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The  use  of genetic  markers  as instrumental  variables  (IV) is  receiving  increasing  attention  from
economists,  statisticians,  epidemiologists  and  social  scientists.  Although  IV  is  commonly  used  in  eco-
nomics,  the  appropriate  conditions  for  the  use  of  genetic  variants  as  instruments  have  not  been  well
deﬁned.  The  increasing  availability  of biomedical  data,  however,  makes  understanding  of these  condi-
tions crucial  to the  successful  use of genotypes  as  instruments.  We  combine  the econometric  IV literature
with  that  from  genetic  epidemiology,  and  discuss  the biological  conditions  and  IV  assumptions  within  the
statistical  potential  outcomes  framework.  We  review  this  in  the  context  of  two  illustrative  applications.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Many studies in the social and epidemiological sciences aim
to make causal inferences using observational data. This is often
problematic, as observed associations are not necessarily causal,
with confounding being an important concern. Randomization
of treatment, as in a Randomized Controlled Trial (RCT), is
one way to infer causality. However, such experiments are not
always possible or feasible. An approach commonly used in the
economics and econometrics literature is that of Instrumental
Variables (IV). This introduces a third variable (the instrument)
that is robustly associated with the risk factor of interest, but
not with the outcome variable, other than through its effect
on the risk factor. This instrument can then be exploited to
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make causal inferences about the effect of the risk factor on the
outcome.
Recently, epidemiologists, statisticians, economists and other
social scientists have become interested in using genetic variants
as instruments. ‘Mendelian randomization’ refers to the random
assignment of an individual’s genotype at conception (Davey
Smith and Ebrahim, 2003; Davey Smith, 2007). Under certain
assumptions that we discuss in detail below, observed associations
between genetic variants and the outcome of interest are unlikely
to be due to confounding by behavioural or environmental fac-
tors. Mendelian randomization can therefore be exploited to make
causal inferences about the effects of modiﬁable (non-genetic)
risk factors, on different outcomes1. Statisticians have highlighted
some of the implicit statistical assumptions commonly made in
Mendelian randomization studies (e.g. Didelez and Sheehan, 2007;
Didelez et al., 2010). Genetic epidemiologists emphasize the impor-
tance of carefully examining the conditions that need to be met  for
genetic variants to be used as instruments (see e.g. Davey Smith
and Ebrahim, 2003; Sheehan et al., 2008; Lawlor et al., 2008a,b).
However, while studies in economics commonly use IV methods,
the (biological) conditions relevant for Mendelian randomiza-
tion have not been disseminated widely in this literature. The
increasing availability of biomedical information in social science
1 Appendix A provides a brief guide to the terms used in genetic studies.
http://dx.doi.org/10.1016/j.jhealeco.2015.10.007
0167-6296/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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datasets, however, makes understanding them crucial to the suc-
cessful use of genotypes as instruments for modiﬁable risk factors.
The contribution of this paper is to discuss these conditions
within the well-known statistical potential outcomes framework.
We use the work by Imbens and Angrist (1994), Angrist et al. (1996),
and Angrist et al. (2000), among others, which has been of great
importance in linking the econometric IV literature to the poten-
tial outcomes framework. We link Mendelian randomization to
this framework, and discuss how the conditions, deﬁned in genetic
epidemiology, relate to the IV assumptions used in statistics and
economics. To communicate best practice in genetic epidemiol-
ogy to a wider economics audience, we review these conditions
in the context of two illustrative applications: one in social science
and one in medicine. Speciﬁcally, we examine whether child fat
masscausally affects (1) academic achievement, and (2) blood pres-
sure, using 32 recently identiﬁed genetic variants as instrumental
variables for fat mass.
These examples are pertinent for several reasons. For our social
science application for example, obese children are more likely to
be absent from school, have sleep disorders, and be treated differ-
ently by teachers, parents and peers. All these may  affect children’s
(learning) environment and educational outcomes. However, an
observed association between fat mass and academic achievement
is not necessarily causal. There are likely to be many confounders,
and one can never be sure that all relevant ones are accounted
for. For our medical application, there is evidence that even rela-
tively small reductions in weight can reduce blood pressure and
hypertension risk (Neter et al., 2003). However, the increase in
obesity in recent decades has been accompanied by a decrease
in hypertension, leading to questions about their association, with
some suggesting that randomized controlled trials of weight reduc-
tion could have affected blood pressure through mechanisms other
than weight loss (Campos et al., 2006). The use of ordinary least
squares (OLS) suggests that fat mass is inversely related to edu-
cational attainment, but increases the risk of hypertension. When
using carefully selected genetic variants as instruments for fat mass,
we ﬁnd no evidence of a causal relationship between fat mass and
academic performance, although the parameters are imprecisely
estimated. In contrast, we ﬁnd a positive effect of fat mass on blood
pressure, suggesting that reductions in fat mass will reduce the risk
of cardiovascular disease.
Although Mendelian randomization is widely used in the med-
ical and epidemiological sciences, with its ﬁndings being fed into
pharmacotherapeutic development, it is very controversial within
economics. This mainly stems from the credibility of the ‘exclu-
sion restriction’: the assumption that the variants do not directly
affect the outcome of interest. Indeed, there are many situations
that may  violate this assumption, invalidating the instruments
and biasing the estimates. One of the issues is that we have
very limited knowledge and understanding of the speciﬁc func-
tions of genes, and studies that directly examine gene-function
are often underpowered. Hence, we can never be certain that the
exclusion restriction is satisﬁed. We  discuss this in detail, and
highlight the speciﬁc (biological) pathways through which the use
of genetic variants as instrumental variables may  lead to invalid
inferences, including the potential for variants to have multiple
functions, or to be correlated to other variants that affect the out-
come of interest. We  also consider the implications of gene–gene
and gene–environment interactions for Mendelian randomization.
Finally, it is worth noting that the uncertainty of the exclusion
restriction is not speciﬁc to Mendelian randomization. Indeed, any
IV analysis relies on this untestable assumption, and one gener-
ally assesses such studies based on whether the available evidence
suggests that the assumption is likely to hold (see also von Hinke
et al., 2012). We  discuss different ways of exploring its validity indi-
rectly in the context of Mendelian randomization and attempt to
clearly articulate the potential situations that would invalidate the
approach2.
Section 2 details the conditions that need to be met for genetic
variants to be used as instruments. Section 3 introduces our empir-
ical application. We  describe the data, examine the validity of our
choice of genetic variants, present the results as well asa number of
sensitivity checks. Section 4 concludes and discusses the implica-
tions of our ﬁndings in terms of best practice for using Mendelian
randomization by researchers who  do not come from a primarily
biological discipline.
2. The use of genetic variants as instrumental variables
We  start by discussing the links between Mendelian randomiza-
tion and other approaches used in the medical and social science
literature. We  then build on the Potential Outcomes Framework by
Imbens and Angrist (1994), Angrist and Imbens (1995), Angrist et al.
(1996, 2000). We  ﬁrst brieﬂy outline the well-known structural
assumptions in the context of our applications, and then discuss
how Mendelian randomization links to the statistical assumptions
of this framework.
2.1. Mendelian randomization
We  discuss Mendelian randomization from a statistics and eco-
nomics perspective in the context of a social study, with the aim
of making causal inferences about the effect of a treatment on
an outcome of interest. Depending on the discipline, the terms
‘treatment’, ‘risk factor’, ‘exposure’, ‘predictor’, or ‘intermediate
phenotype’ have all been used to denote the variable of interest that
potentially causes the outcome. To avoid confusion, the remainder
of this paper uses either the term ‘treatment’ or ‘risk factor’.
The concept of Mendelian randomization is closely linked to
Randomized Controlled Trials (RCTs), where the allocation of treat-
ment is randomized over all eligible individuals (Davey Smith and
Ebrahim, 2005; Hingorani and Humphries, 2005). Indeed, IV can be
applied to analyse encouragement designs (such as RCTs where the
instrument is the encouragement to participate) that are affected
by non-ignorable non-compliance. Non-compliance refers to the
fact that individuals can choose to take or not take treatments
other than those to which they are randomized. Non-ignorable non-
compliance refers to participants choosing to take or not to take
the treatment that they are randomized to in a manner associated
with their study outcomes, after adjusting for baseline characteris-
tics. This is also known as endogenous treatment in economics, or
selection into treatment.
The idea is similar for the social context in our application:
individuals ‘select’ their treatment – fat mass – through lifestyle
choices, such as diet and physical activity, which are likely to
be related to their study outcome (educational attainment and
blood pressure). In a well-conducted RCT of an intervention aimed
at reducing fat mass, the random allocation effectively balances
these lifestyle choices between groups. Comparing groups based
on the original random allocation (‘intention to treat’) maintains
this balance, whereas comparing groups based on what treatment
was actually chosen by the participant (a ‘per-protocol’ analy-
sis) is likely to be biased due to non-ignorable non-compliance.
In other words, treatment by choice (as opposed to treatment by
randomization) is likely to be related to the outcome through char-
acteristics such as social class, income, diet, etc.
There are many cases, however, where RCTs are infeasible (for
example, there may  be no effective intervention to randomize, such
2 Thus we give below examples of situations where the use of genetic variants as
instrumental variables is more as well as less likely to lead to incorrect inference.
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as for adiposity) or unethical (for example, when examining the
effect of prenatal alcohol consumption on different outcomes). In
such cases, quasi-experimental designs such as Mendelian random-
ization experiments can provide a useful alternative approach.
As in RCTs, Mendelian randomization assumes that character-
istics such as social class, income and diet are balanced across the
genotypes. This assumption exploits the fact that there is an equal
probability that either parental allele (see Appendix A) is transmit-
ted to offspring. As this allocation is random at the family trio level,
the cleanest experiment is one with biological siblings, examining
randomization of genes within families (Davey Smith and Ebrahim,
2003). However, also at a population level, many studies suggest
that genetic variants are largely unrelated to the many socioeco-
nomic and behavioural characteristics that are closely linked with
each other and that confound conventional observational studies
(Bhatti et al., 2005; Davey Smith et al., 2008; Kivimäki et al., 2008;
Lawlor et al., 2008a,b; von Hinke et al., 2014; see also Fisher, 1952;
Box 2010). Hence, as genes are randomly assigned during meiosis
(cell division for reproduction), individuals of different genotypes
are expected not to differ systematically in any other respect. The
issue of compliance in Mendelian randomization studies is dis-
cussed further in Section 2.2.
Interventional studies such as RCTs, where treatment is
introduced at a certain age, identify the effect of differences in
treatment from that point in time. By contrast, estimates from
Mendelian randomization experiments exploit differences in treat-
ment throughout life, estimating the long term (cumulative) effects
of the treatment on the outcome of interest (Davey Smith and
Ebrahim, 2005).
As noted by Didelez and Sheehan (2007), the potential limita-
tions of Mendelian randomization studiesfall into two sets. First,
limitations related to the implicit statistical assumptions common
in many Mendelian randomization studies, such as linearity and
additivity. As these have been discussed in detail (e.g. Didelez and
Sheehan, 2007; Didelez et al., 2010), we focus on the second set of
limitations: those relating to the assumptions of the validity of the
instrument. Genetic epidemiology studies emphasize the impor-
tance of carefully examining several situations and (biological)
processes that may  violate the IV assumptions (see e.g. Davey Smith
and Ebrahim, 2003; Sheehan et al., 2008; Lawlor et al., 2008a,b). The
increasing availability of biomedical information in social science
datasets makes understanding of these conditions crucial to the
successful use of genotypes as instruments for modiﬁable risk fac-
tors. We  therefore ﬁrst outline the structural assumptions in the
context of our applications, discuss the concepts deﬁned in epi-
demiology and relate them to the assumptions that need to be
met  to obtain causal estimates of the effect of the risk factor on
the outcome of interest, as deﬁned in the statistics and economics
literature.
2.2. The potential outcomes framework
Our two illustrative applications use a continuous treatment
and outcome variable, and 32 independent genetic variants.
For ease of exposition, however, we discuss our framework for
the case of two genetic variants, though we  note that this is
easily generalized to incorporate any number of variants. As
shown in Angrist et al. (2000), with such discrete instruments,
the number of instruments is irrelevant; it is the number of
distinct values of the instrument vector that matters. Hence,
with two genetic variants (denoted by Z1 and Z2), we observe
nine instrumental values, deﬁned by the combination of the
number of rare alleles. Without loss of generality, we order
the instruments by their mean fat mass, for example: (Z1, Z2)
∈
{
(0, 0) , (0, 1) , (1, 0) , (0, 2) (1, 1) , (1, 2) , (2, 0) , (2, 1) , (2, 2)
}
.
We can represent this as an instrument Z with support 1,2,. . .,9;
the full set of instruments are the nine mutually exclusive
dummy  variables. Let A and Y denote random variables repre-
senting, respectively, fat mass and the educational outcome/blood
pressure.
Let Ai (z) be the potential fat mass for individual i when the
instrument is set to z. Only one of the 9 possible treatment
assignments Ai (1) , Ai (2) , . . .,  Ai (9) is ever observed for any one
individual. Similarly, let Yi (z, a) be the potential outcome for indi-
vidual i that would be obtained if i‘s fat mass, the treatment variable,
was set to a and the instrument was  set to z. We  refer to Ai (z)
and Yi (z, a) as the potential treatments and potential outcomes
respectively. Similar to Ai (z), only one of the 9 potential outcomes
Yi (1, Ai (1)) , Yi (2, Ai (2)) , . . .,  Yi (9, Ai (9)) can ever be observed for
any one individual.
We follow convention and assume that individual i’s potential
treatments and potential outcomes are independent of the out-
come and treatment status of other individuals. This is also referred
to as the Stable Unit Treatment Value Assumption (SUTVA, see e.g.
Rubin, 1980).
Given the set of potential outcomes, we can deﬁne the
causal effects for individual i of Z on A as (Ai (z) − Ai (z − 1)),
and the causal effects for individual i of Z on Y as
(Yi (z, Ai (z)) − Yi (z − 1, Ai (z − 1))), for z ∈
{
2, . . .,  9
}
. These
are also known as the intention-to-treat effects.
Assumption 1 (Independence).
Zi⊥
{
Yi (z, a) , Ai (z)
}
z,a
The independence assumption implies that the instrument is
independent of all potential outcomes and potential treatments,
for all values of z and a. In other words, the instrument is as good
as randomly assigned. Note that, as Mendelian randomization is
closely related to RCTs, where the allocation of treatment is ran-
domized over all eligible individuals, we specify the unconditional
independence assumption. If the instruments are not independent
of covariates, however, we require the conditional independence
assumption, implying that independence holds conditional on
some vector of covariates, deﬁned by X. We  discuss the role of
covariates in Mendelian randomization studies in more detail in
Section 2.4.
Given SUTVA and independence, we can obtain unbiased esti-
mators for the average intention-to-treat effects by taking the
difference of sample averagesof the outcomes and treatments at
different values of the instrument.
Assumption 2 (Exclusion).
Yi (z, a) = Yi
(
z′, a
)
, for all z, z′ and for all a.
This implies that Yi (1, a) = Yi (2, a) = . . . = Yi (9, a), for all a,
or that the potential outcomes, at any level of fat mass a, are
unchanged by the value of the instrument. In other words, the only
way through which the instrument affects the potential outcome is
via A. It implies that Yi (z, a) is a function of a only, and hence we  can
write Yi (z, a) = Yi (a) . If the exclusion restriction only holds condi-
tional on X, we  can specify the exclusion restriction conditional on
these covariates.
With heterogeneous responses, the potential outcomes for indi-
vidual i can be written as a general function of a, say Yi (a) ≡ gi (a) .
We can deﬁne the individual causal effects of A on Y as the deriva-
tives of gi (a) . So the individual causal response is the difference in
potential outcomes at each value of a.
Although we  can never observe any of these individual
causal effects, we can observe the average causal effects for
groups of individuals who  can be induced to change treatment:
E
[
g′
i (q) |Ai (z) < q < Ai (z′)
]
, where g′
i (q) is the derivative of gi (a)
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w.r.t. a evaluated at q. Inferences about such average causal effects
are made using changes in treatment status that are induced by the
instrument (Angrist et al., 1996). For this, we require the instrument
to affect treatment status.
Assumption 3 (Non-zero effect of the instrument on treatment).
E
[
Ai (z) − Ai
(
z′
)]
/= 0, for all z, z′
This implies that expected potential fat mass is affected by the
instrument and therefore that the instrument has an effect on the
treatment.
Assumption 4 (Monotonicity).
P [Ai (z) ≥ Ai (z′)] = 1 for all z ≥ z′ or
P [Ai (z) ≤ Ai (z′)] = 1, for all z ≤ z′,
for all i. This implies that the potential fat mass for individual i with
instrument value z is at least as high as the potential fat mass for
the same individual with instrument value z′, or vice versa, that the
potential fat mass for individual i with instrument value z is lower
than or equal to the potential fat mass for the same individual with
instrument value z′, for all i.
We use the above assumptions to interpret differences in aver-
age outcomes and treatments at different values of the instrument.
Under these assumptions, the IV estimand is equal to a weighted
average of the 8 linearly independent average causal responses
(ACRs), deﬁned here as z,z−1:
z,z−1 =
E [Yi|Zi = z] − E [Yi|Zi = z − 1]
E [Ai|Zi = z] − E [Ai|Zi = z − 1]
=
∫
E
[
g′i (q) |Ai (z − 1) < q < Ai (z)
]
P
{
Ai (z − 1) < q < Ai (z)
}
dq
∫
P
{
Ai (z − 1) < q < Ai (z)
}
dq
,
for z = 2, . . .,  9.
In other words, each instrumental variable identiﬁes a unique
causal parameter, one speciﬁc to the subpopulation whose treat-
ment is affected by the instrument. Different valid instruments may
thereforelead to different causal parameters. Hence, IV estimation
that uses each of the instruments one by one weights the deriva-
tive function g′
i (q) by the strength of the instrument (Angrist et al.,
2000; Angrist and Pischke, 2009). Let the points of support of Z be
ordered such that l < m implies that E [Ai|Zi = l] < E [Ai|Zi = m] .  The
IV estimand using all 9 mutually exclusive instruments can then be
written as:
9∑
z=2
ωzz,z−1 (1)
where
ωz = (E [Ai|Zi = z] − E [Ai|Zi = z − 1])
·
∑9
l=zl (E [Ai|Zi = l] − E [Ai])∑9
l=1lE [Ai|Zi = l] (E [Ai|Zi = l] − E [Ai])
and l = Pr [Z = l], ωz > 0 and
∑
zωz = 1. Hence, it averages the
(pairwise) instrument-speciﬁc weighted averages of the derivative
function, where the weights are proportional to the instrument-
induced change in the cumulative distribution function (CDF) of
fat mass (Angrist and Imbens, 1995; Angrist et al., 2000; Angrist
and Pischke, 2009). In other words, it combines a set of weighted
average effects into a new weighted average.
The above example is for a case with two genetic variants, or
nine instrumental variables, which is straightforward to estimate
in standard software packages. As discussed earlier, however, we
observe 32 genetic variants, and with that, a maximum of 332
instrumental variables3. Instead of specifying a model with that
many instruments, we  use one ‘allelic score’, mapping the instru-
mental variables z = 1, . . .,  332 onto a function h (Zi) , deﬁned as the
number of risk alleles carried by each child. In other words, for every
individual, we  sum the number of adiposity-increasing alleles for
the 32 variants. For example, the allelic score for the above case of
9 instruments takes ﬁve values:
(Z1, Z2) h (Zi)
(0, 0) 0
(0, 1) , (1, 0) 1
(1, 1) , (0, 2) , (2, 0) 2
(1, 2) , (2, 1) 3
(2, 2) 4
(in our sample, the allelic score using the 32 genetic variants
takes one of 28 distinct values, see also Section 3.4). Using the allelic
score h (Zi),  the IV estimand can be written as:
Cov (Yi, h (Zi))
Cov (Ai, h (Zi))
.
Similar to (1), the IV estimand that uses the multivalued allelic
score h (Zi) is a weighted average of the ACRs z,z−1. However, the
weights are now given by:
ωz =
(E [Ai|Zi = z] − E [Ai|Zi = z − 1]) ·
∑9
l=zl (h (Zi = l) − E [h (Zi)])∑9
m=1 (E [Ai|Zi = m] − E [Ai|Zi = m − 1]) ·
∑9
l=ml (h (Zi = l) − E [h (Zi)])
,
where, again, l = Pr [Z = l], ωz > 0 and
∑
zωz = 1 As above, the
weights are proportional to the ﬁrst stage impact on the treat-
ment (Angrist et al., 2000). Thus, inferences about the ACRs are
made using changes in treatment status that are induced by the
instrument.
At this point, it may  be useful to consider a situation where the
instrument and treatment are binary, in which case we can strat-
ify individuals into four latent groups, as commonly used in the
econometrics literature (e.g. Angrist et al., 1996): those who are
induced to take treatment by the instrument (compliers), those who
do the opposite of their assignment (deﬁers), those who never take
treatment, whatever their assignment (never-takers), and those
who always take treatment, regardless of their assignment (always-
takers).  In this framework, the IV estimate can be interpreted as a
Local Average Treatment Effect (LATE) or Complier Average Causal
Effect (CACE): the effect of treatment for those who  are induced to
take treatmentby the instrument (the compliers). Indeed, LATE or
CACE is not informative about effects on never-and always-takers,
because (by deﬁnition) treatment status for these groups is not
affected by the instrument. By virtue of the exclusion restriction,
the causal effect of Z on Y for never-takers and always-takers is zero.
And by virtue of the monotonicity assumption, there are no deﬁers.
Note that in the case of a continuous intermediate variable as gen-
erally used in Mendelian randomization studies (such as fat mass,
lipids, energy intake, units of alcohol, number of cigarettes, etc.), it
is unclear what it means to be a complier, deﬁer, always-taker, or
never-taker. A detailed discussion on identifying compliers in such
cases is beyond the scope of this paper, but for different approaches,
we refer the reader to Frangakis and Rubin (2002), Sjölander et al.
(2009), Jin and Rubin (2008), and Bartolucci and Grilli (2011).
3 Note that not all combinations of rare alleles may  be observed in the data, reduc-
ing  the total number of instruments. In addition, when multiple pairs of risk alleles
give the same predicted treatment, one may  condense the number of instrument
values, leading to a further reduction in the total number of instruments (see Clarke
et  al., 2015).
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2.3. Conditions for the use of genetic variants as instrumental
variables
For a valid causal interpretation of the IV estimand that uses
the genetic variants as instruments, we require the above assump-
tions to hold. However, there are various situations that may  violate
them, which need to be examined. We  discuss these below.
Assumption 1 (Independence). Although genotypes are randomly
allocated at conception, the allele distribution may  differ for
different population subgroups. If these subgroups also have sys-
tematically different outcomes of interest, this could lead to an
association between the two at the population level without an
actual causal relationship. A systematic relationship between the
allele frequency and the outcome of interest across different sub-
populations is also referred to as ‘population stratiﬁcation’. For
example, allele frequencies can vary across ethnic groups. Any
systematic differences in the outcome of interest across these
subpopulations that are not due to the genetic make-up may
therefore lead to biased estimates of the effect of treatment by
violating the independence Assumption 1. In other words, despite
the fact that genotypes are randomly allocated and with that sat-
isfy independence, any population stratiﬁcation can violate this
assumption. This can be dealt with, however, by examining the
question of interest within ethnic groups, separately analyzing the
different subpopulations, and/or adjusting for principal compo-
nents from genome wide data that function as ancestry markers.
These approaches then relyon the conditional independence
assumption, assuming independence conditional on ethnicity or
ancestry.
As genotypes are randomly assigned given the parental genes,
the presence of assortative mating based on genes can violate
independence. The cleanest experiment, therefore, is one with
biological siblings, examining randomization of genes within fam-
ilies (Davey Smith and Ebrahim, 2003). However, even when we
only observe one individual per family, Mendelian randomiza-
tion is valid if we are able to assume that, at the population
level, genetic variants are unrelated to other characteristics that
may  affect the outcome of interest, as shown in many studies
(Bhatti et al., 2005; Davey Smith et al., 2008; Kivimäki et al.,
2008; Lawlor et al., 2008a,b; von Hinke et al., 2014; see also
Fisher, 1952). One way to indirectly test independence is by explor-
ing whether the distribution of observable characteristics is the
same in different groups deﬁned by the value of the instrument
(i.e. different genotypes). Indeed, if the instrument is random-
ized, there should be no systematic variation in the covariates by
genotype, whether we use a within- or between-family analysis.
This raises the question however, about which covariates to test
for, as any characteristic is, in principle, a post-treatment variable
with respect to the instrument. Hence, any systematic variation
in these indirect tests does not necessarily indicate a violation
of independence (see also Rubin, 2005). It may  be, for example,
that the instrument is picking up other causal effects of the same
treatment.
Assumption 2 (Exclusion).  One can never directly test whether
exclusion holds, and there are various situations in which Assump-
tion 2 fails, invalidating the instruments. One such situation is that
‘behaviours’ may  be affected by the genotype. As individuals inherit
their genes from their parents, it may  be important to consider
whether parents’ behaviours or preferences are affected by their
genotype (and hence their offspring’s genotype). This can bias stud-
ies that examine maternal behaviours that inﬂuence the outcome
of interest via intrauterine effects. Likewise, it may  be a problem
in studies where parental behaviours inﬂuence the outcomevia
affecting their (child’s) behaviour.
As an example of the former, if one were interested in the
effect of an individual’s alcohol consumption on their later life
liver disease using a genetic variant that robustly relates to alcohol
intake, any intrauterine effects of maternal alcohol consumption
during pregnancy on offspring liver development could violate
Assumption 2. This is because the mother’s genotype is related to
the offspring’s genotype (the instrument), and will inﬂuence her
alcohol consumption throughout life, including potentially when
she was  pregnant. If maternal alcohol intake during pregnancy
affects her offspring’s liver development in utero and its functioning
later in the child’s life, there is a link from the offspring’s geno-
type (IV) to the outcome (the offspring’s liver disease) via maternal
genotype and maternal alcohol consumption, violating Assumption
2.
As an example of the latter, if one is interested in the effect of
fat mass on education, as we are below, parents who carry ‘fat’
alleles may  be discriminated against in the labour market because
of their on average higher weights (Cawley, 2004). If this affects
their behaviour or preferences for their child’s weight or education,
Assumption 2 may  be violated.
A second situation relates to the mechanisms through which
genetic variants affect the modiﬁable risk factor. These are often
unknown. If the mechanism involves changes in behaviour or pre-
ferences that in addition to affecting the risk factor also directly
affect the outcome, Assumption 2 will be violated. For example,
if the fat related genetic variants that we  use below inﬂuence fat
mass because they are related to pathways associated with addic-
tion more generally, such as addiction to high energy foods, and if
the latter affects the outcome of interest, Assumption 2 would be
violated. If the mechanism only results in changes to the risk factor
but does not directly affect the outcome, the exclusion restriction
is not violated.
Thirdly, the genetic instrument may  be related to other genetic
variants that affect the outcome of interest. Mendel’s second law
states that the inheritance of one trait is independent of the inher-
itance of another. However, it has been shown that this does not
always hold and that some variants are likely to be co-inherited.
This so-called ‘Linkage Disequilibrium’ (LD) does not occur for
genetic variants on different (non-homologous) chromosomes, and
the degree of LD is partly a function of the distance between the
loci (see Appendix A for some of the genetic terms used here).
Depending on the effects of the co-inherited variant, LD can bias
the estimates. If our instrument is in LD with another polymorphic
locus that affects only the modiﬁable risk factor, the IV estimates
remain consistent. However, if it is in LD with a polymorphic locus
that directly affects the outcome, Assumption 2 is violated. Relat-
edly, there is the situation of ‘pleiotropy’, where one genetic variant
has multiple functions. The case is similar to that of LD, and will
invalidate the IV approach if the pleiotropic effect inﬂuences the
outcome directly, but not if it affects only other characteristics that
are unrelated to the outcome of interest.
Fourth, a biological process that may  bias causal estimates in
Mendelian randomization studies is ‘canalization’. This refers to
the reduced sensitivity of a phenotype to the changes in underly-
ing genetic and non-genetic factors that determine its expression.
Hence, a canalized genotype produces the same (or a similar) phe-
notype in different genetic and non-genetic backgrounds (Flatt,
2005). For example, an individual who has a genetic variant asso-
ciated with higher blood pressure may not experience adverse
phenotypic effects of high blood pressure due to the arteries becom-
ing resistant. This is difﬁcult to test for, as the genetic variant may
still be related to blood pressure, but any adverse health outcomes
(phenotypes) normally caused by higher blood pressure would not
occur. Hence, canalization implies that the genotype can affect
the outcome through alternative channels, altering the associa-
tion between genotype and outcome, without any change in the
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genotype-risk factor relationship. Canalization, therefore, canvio-
late the exclusion restriction.
These different potential violations of Assumption 2 indicate
that, as the speciﬁc functions of genetic variants and the mecha-
nisms through which they affect individuals are often unknown,
one can never claim that exclusion holds. Indeed, one can only test
exclusion indirectly; we discuss this in more detail in Section 2.5
below.
Assumption 3 (Non-zero effect of the instrument on treatment).  A
valid instrument must be associated with (i.e. have a non-zero
effect on) the risk factor of interest. Mendelian randomization
can only be used with genetic variants that have been robustly
shown to affect the risk factor. This point is especially important,
as many initial genotype-risk factor associations fail to replicate
(Colhoun et al., 2003). Without a consistent population associa-
tion, even if a sample correlation exists, Assumption 3 may  be
violated. Indeed, choosing SNPs merely based on the sample asso-
ciation with the risk factor (rather than using information external
to the study) can lead to biased IV estimates (Taylor et al., 2014).
It is therefore important that Mendelian randomization studies
only use genetic variants that have been shown to be robustly
associated with the risk factor in a large number of independent
studies.
However, even if a suitable genetic instrument is available, it
may  explain little of the variation in the observed risk factor. A
weak association could result in a biased IV estimate and has impli-
cations for statistical power. If the alleles shift the distribution of
risk factor by a very small amount, the effect of the risk factor on
the outcome is identiﬁed only by this small difference, emphasiz-
ing the need either for very large sample sizes, especially when the
average causal effect of the risk factor on the outcome could be
small, or many genetic variants that can be combined into a more
powerful instrument. This, of course, is not a problem speciﬁc to
Mendelian randomization, but refers to a more general problem of
weak instruments (see e.g. Bound et al., 1995; Staiger and Stock,
1997; Stock et al., 2002).
Assumption 4 (Monotonicity).  Whether monotonicity is satisﬁed
relies on knowing each individual’s counterfactual and therefore
always remains an assumption. Monotonicity may  be violated
in the presence of gene–environment interactions; i.e. when the
effect of the environment on the risk factor differs depend-
ing on individuals’ genetic predisposition, or when individuals’
genetic predispositions are expressed differently in different envi-
ronments. For example, if the expression of a genetic variant
that increases fat mass depends on individuals’ awareness of the
importance of nutrition for one’s health, monotonicity may  be
violated when the potential fat mass of an individual with the
genetic variant in an (e.g. educated) environment is less than the
potential fat mass for the same individual in that environment
without the genetic variant. However, if the expression of the
variant is simply reduced in the educated environment, mono-
tonicity would not be violated, as the potential adiposity of an
individual with the genetic variant remains at least as high as the
potential adiposity for the same individual without the genetic
variant.
2.4. The role of covariates in mendelian randomization
experiments
There is a large literature on the use of covariates in IV. Eco-
nomics and social applications of IV generally include a wide set of
control variables; the main motivation being that the conditional
independence and exclusion restriction are more likely to be valid.
A second reason for including covariates in many economics and
social applications of IV is that it may  reduce the residual variability
of the dependent variable, leading to more precise estimates.
The situation is somewhat different, however, in RCTs/
encouragement designs, and in Mendelian randomization stud-
ies. When covariates enter the assignment mechanism in
RCTs/encouragement designs, such as when randomization takes
place within certain strata, these covariates should be controlled
for, relying on the conditional independence assumption. The inclu-
sion of further baseline covariates may  in addition increase the
precision of the estimates. In Mendelian randomization stud-
ies, however, there are no baseline covariates. Furthermore, as
covariates do not enter the assignment mechanism, assignment
is independent of covariates, and we can rely on the uncon-
ditional independence assumption. Therefore, conditioning on
covariates is not necessary in Mendelian randomization exper-
iments. The exception, however, is when there is population
stratiﬁcation. In this case, the analyses should be done within
population subgroups, or should adjust for principal components
from genome wide data, relying on the conditional independence
assumption.
Although one may  choose to adjust for covariates to increase
precision, this raises the issue of which covariates to include in a
Mendelian randomization study, as any characteristic is, in prin-
ciple, a post-treatment variable with respect to the instrument,
and – with that – may  be affected by the instrument. If the instru-
mented treatment has multiple causal effects, or if the outcome
has a causal effect of its own, adjusting for such post-treatment
variables may  lead to biased estimates of the causal effect. Indeed,
we should not control for any ‘downstream’ (behavioural) covari-
ates that are potentially affected by the treatment or outcome.
Thus, we  only control for 10 ancestry-informative principal com-
ponents in our main analyses, though we report the estimates
that adjust for further covariates in the sensitivity analysis. Under
independence, and when the instrumented treatment and out-
come do not affect these covariates, the unadjusted and adjusted
IV estimates should be similar, though the latter may be more
precise.
2.5. Testing the exclusion restriction
There is no direct test for the validity of the exclusion restriction
(Assumption 2). In other words, its validity will never be known
with certainty and can only be examined indirectly or falsiﬁed
by the data. To this end, however, Mendelian Randomization is
no different from any other (non-genetic) IV study; the exclusion
restriction always remains an assumption. However, one of the dif-
ferences, one may  argue, is that the speciﬁc functions of genetic
variants and the mechanisms through which they affect individuals
are often unknown, making it more difﬁcult, if not impossible, to
argue that the instrument is valid. However, with a rapidly grow-
ing medical literature, our knowledge on the speciﬁc function of
variants is increasing. For example, much is now known about the
function of certain variants in the metabolism of alcohol, leading
to clear predictions from the medical literature on how they affect
individuals’ alcohol consumption. But knowing the exact function
of a variant is not sufﬁcient. Indeed, the variant may be pleiotropic,
and its pleiotropic effects may have not yet have been identiﬁed,
potentially invalidating the instrument.
Similar to other IV studies that use multiple instruments, how-
ever, Mendelian randomization allows for potential violations
through pleiotropy or LD (though not necessarily canalization) to
be tested when data is available on a large number of genetic
instruments. More speciﬁcally, if multiple IV models – each using
different combinations of these variants – predict the same causal
effect, it is unlikely to be due to some common pleiotropy or LD
across the different sets of variants, assuming that the different
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variants are located on different chromosomes and affect the trait
via different pathways (Davey Smith, 2011; Palmer et al., 2011;
von Hinke et al., 2013). Hence, consistency between such estimates
provides evidence against potential pleiotropy or LD-induced con-
founding. However, obtaining different causal effects with different
combinations of variants does not necessarily point to a violation
of the exclusion restriction, as variability in treatment effects may
occur due to different compliant subpopulations for the different
instrument sets (i.e. different LATEs or CACEs).
Alternatively, one can view Mendelian randomization with mul-
tiple instruments as analogous to a meta-analysis of separate
study results. Just like the IV estimate using multiple instrumen-
tal variables is a weighted average of the individual IV estimates,
a meta-analysis is a weighted average of multiple studies. Bowden
et al. (2015) show that, in this setting, Egger regression (a tool to
detect small study bias in meta-analysis) can be adapted to test
for bias from pleiotropy. In addition, it can provide an estimate of
the causal effect of the treatment on the outcome of interest, even
when the genetic variants are invalid.
In a constant effects model, one can indirectly test whether the
exclusion restriction holds using an ‘over-identiﬁcation’ (Sargan or
Hansen) test (Sargan, 1958; Hansen, 1982), provided that there are
more instruments than endogenous variables. Note, however, that
this is not a test that the instruments are indeed valid. A problem
with the over-identiﬁcation test is that it has low power, especially
when the underlying IV estimates are imprecise. In our heteroge-
neous treatment effects framework however, over-identiﬁcation
tests are inappropriate, even when the underlying estimates are
precise, as a rejection of the test need not imply a violation of the
exclusion restriction. As discussed above, it may  point to treatment
effect heterogeneity, as different valid instruments may  estimate
different parameters, with the ﬁnal IV estimate being a weighted
average of the different treatment effects. Hence, although we
report the test statistic below, we cannot necessarily interpret it
in a heterogeneous treatment effects framework.
Note that, although canalization refers to a violation of the
exclusion restriction, it cannot necessarily be tested using over-
identiﬁcation tests. Similar to the above, a rejection cannot
distinguish between treatment effect heterogeneity and canaliza-
tion. In fact, there is no (clear) way of testing or correcting for
canalization. However, for the complex traits that are largely of
interest in Mendelian randomization studies, there is no evidence
that canalization occurs in humans (Davey Smith and Ebrahim,
2003).
2.6. Previous studies in the economics literature
The existing economics literature includes three studies that
exploit genetic variation to identify the effects of BMIon economic
outcomes. Ding et al. (2009) examine the effects of several health
conditions, one of which is BMI, on adolescents’ academic achieve-
ment. Their IV results show large and signiﬁcant negative effects on
girls’ Grade Point Average (GPA), but not for boys. GPAs for obese
girls are on average 0.8 points lower than for non-obese girls. They
use four genetic variants as instruments: the dopamine transporter
(DAT1) and D2 receptor (DRD2), tryptophan hydroxylase (TPH) and
cytochrome P4502B6 (CYP2B6). Fletcher and Lehrer (2011) take a
similar approach to Ding et al., but use the Add Health data to
exploit within-family genetic inheritance. They ﬁnd no evidence
that obesity affects academic achievement. In addition to DAT1 and
DRD2,  their instruments include the dopamine D4 receptor (DRD4),
the serotonin transporter (5HTT), monoamine oxidase (MAOA) and
cytochrome P4502A6 (CYP2A6). Finally, Norton and Han (2008)
examine the effects of BMI  on labour market outcomes using DAT1
and DRD4 as instruments for BMI  and ﬁnd no evidence of a causal
association.
The discussion in Section 2.3 above highlights the importance of
the choice of genetic variants in Mendelian randomization experi-
ments. Although the validity of the exclusion restriction can never
be tested directly, it is unlikely that genes related to neurotrans-
mitters such as dopamine receptors and serotonin transporters are
valid instruments. The inherent problem is that neurotransmitters
are implicated in many different neurological processes. Hence, it is
difﬁcult to argue that they can be used as valid instruments for one
speciﬁc risk factor without being associated with others that could
plausibly inﬂuence the outcome of interest (Cawley et al., 2011;
von Hinke et al., 2011).
More generally, however, Mendelian randomization can only
be used with genetic variants that have been robustly shown to
affect the risk factor (Assumption 4), relying on prior knowledge
about the association between the genotype and risk factor. The
choice of instruments in the studies cited above, however, seems
to be data-derived: using either forward stepwise estimation (Ding
et al.) or selecting those SNPs that have nominally statistically sig-
niﬁcant sample correlations in the ﬁrst stage (Fletcher and Lehrer).
Furthermore, both Ding et al. and Fletcher and Lehrer acknowl-
edge that there is weak and inconsistent evidence in the medical
literature, based on very small unrepresentative clinical samples,
of the association between their genetic variants and health sta-
tus or behaviours. Indeed, the IV strategy is invalid when relying
only on such sample associationsand leads to biased results (Taylor
et al., 2014). Norton and Han (2008) base their selection of SNPs
on a study by Guo et al. (2006), who  ﬁnd a negative association
between the D4.7/D4.7 genotype of DRD4 and obesity. This rela-
tionship, however, has not been replicated in other independent
studies (see for example Hinney et al. (1999), or Fletcher and Lehrer
(2011) who ﬁnd an insigniﬁcant but positive association; see also
Lawlor et al., 2008a).
To our knowledge, there are no studies in economics that
explore the effects of BMI  on blood pressure. However, the relation-
ship has been explored in the medical literature. Indeed, Timpson
et al. (2009) use two genetic variants, FTO and MC4R, as instruments
for BMI  to explore the effects on blood pressure and hypertension
risk. Using those aged 20 and over from the Copenhagen General
Population Study, they ﬁnd that BMI  increases both systolic and
diastolic blood pressure. We  are, however, not aware of any studies
exploring this relationship for children or adolescents.
3. Application: The effect of fat mass on academic
performance and blood pressure
3.1. Data
Our data are from a cohort of children born in one geographic
area (Avon) of England. Women  eligible for enrolment in the
population-based Avon Longitudinal Study of Parents and Children
(ALSPAC) had an expected delivery date between 1 April 1991 and
31 December 1992. Approximately 85% of these mothers enrolled,
leading to about 14,000 pregnancies. The Avon area has approxi-
mately 1 million inhabitants and is broadly representative of the
UK as a whole, though slightly more afﬂuent than the general
population4. Detailed information on the study children and their
families has been collected using a variety of sources, including
self-completed questionnaires, data extraction from medical and
educational records, in-depth interviews, and biological samples.
Note however, that ALSPAC is a cohort; as such, there is no system-
atic data collection on siblings.
4 For more information on the representativeness of ALSPAC, its enrolment and
response rates, see Boyd et al., 2012; Fraser et al., 2012; and www.bristol.ac.uk/
alspac.
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A total of 12,620 children survived past the age of 1 and returned
at least one questionnaire. Of these, we exclude 642 children
because either their mother or father is of non-white ethnic origin
(to avoid potential population stratiﬁcation), leaving 11,978 poten-
tial participants. Our sample selection process is as follows. First,
we select children for whom we observe their genotypes and 10
ancestry-informative principal components, leaving us with 7335
children. Second, we drop children with missing data on fat mass.
We further restrict the sample to children for whom we observe
their educational outcomes and blood pressure, leading to a ﬁnal
sample size of 4844 and 4047 children, respectively.
Attrition in the ALSPAC cohort is known to be correlated with
socio-economic position, with children from lower educated, lower
income families more likely to drop out (Boyd et al., 2012; Fraser
et al., 2012). Attrition can bias our analyses if observations are lost
in a non-random manner. We  explore attrition more generally in
Table 1. Column 1 shows the descriptive statistics for the full sam-
ple of children for whom data is available. Column 2 shows the
statistics for the sample with genetic information, and column 3
and 4 use the ﬁnal estimation sample for educational outcomes
and blood pressure respectively. We  conﬁrm the socio-economic
gradient in attrition: children in the estimation sample do signiﬁ-
cantly better in school, based on their Key Stage 3 (KS3) tests, their
families are wealthier than the original sample, of higher socio-
economic position, and their mother are higher educated and older,
with fewer mental health problems. Hence, there are considerable
differences in the distribution of observables between the original
and estimation samples. Note, however, that we ﬁnd no evidence
of any selection or non-random attrition based on genetic variants,
whether we use an unweighted or weighted score, or the 32 indi-
vidual variants. Furthermore, there are no signiﬁcant differences
in children’s blood pressure and fat mass between the different
samples. Hence, although our analyses may  be based on a selected
sample of individuals, potentially limiting its generalizability, any
attrition is unrelated to the genotypes used here.
3.2. Measures of academic achievement, blood pressure, fat mass,
and the genetic variants
Our ﬁrst outcome measure is the child’s Key Stage 3 (KS3) score.
The KS3 exam is a nationally set exam, taken by all 14-year-olds
in English state schools. This measure of children’s performance is
therefore objective and comparable across all children. Their scores
for three subjects (English, maths and science) are obtained from
the National Pupil Database, a census of pupils in England in the
state school system, which is matched into ALSPAC. We  use an aver-
age score for the three subjects, standardized on the full sample
of children for whom data is available, with mean 100, standard
deviation 10.
Our second outcome measure is the child’s blood pressure, mea-
sured in millimetres of mercury (mmHg) at age 13. We  observe
both systolic (maximum) and diastolic (minimum) blood pressure,
measured by trained nurses. Blood pressure was measured twice
at the clinic; we use the average of the two readings to reduce
measurement error.
Our main measure for child fat mass, our risk factor of interest,
is the child’s body fat mass (adjusted for age in months, height and
height squared), as measured by a dual-energy X-ray absorptiome-
try scan (DXA) at age 11. As fat mass is measured two to three years
prior to the outcomes of interest, this avoids potential problems
related to reverse causation. The DXA scan scans the whole body,
dividing it into fat, lean tissue, and bone mass. We  standardize fat
mass on the full sample of children for whom data are available,
with mean 100 and standard deviation 10.
For the genetic variants, we use 32 SNPs that have been con-
sistently found to relate to body weight and fat mass (Speliotes
et al., 2010; see below)5. There are different ways to include these
instruments in our analyses, though each of these has poten-
tial drawbacks. For example, we may  use the 32 variants or the
64 adiposity-increasing alleles as separate instrumental variables,
potentially leading to weak instrument bias, as the effect of each
individual variant or allele on adiposity is small. Alternatively, we
could use a count of the total number of risk alleles carried by
each individual (an ‘allelic score’), increasing the strength of the
instruments. However, this imposes an equal effect size for every
allele, which is not necessarily supported by the data. Similarly, we
could deﬁne multiple instruments as separate dummy variables
indicating the number of risk alleles carried by each individual.
Although this allows for different numbers of risk alleles to have
different effect sizes, it assumes that the effect of carrying e.g. four
risk alleles is the same no matter which four they are. We  could
also use a weighted allelic score, where the weights are deﬁned by
the effect size of each particular variant on adiposity, as estimated
in an independent meta-analysis.
The evidence suggests that allele scores give unbiased esti-
mates and are more efﬁcient than using the individual variants.
There is some loss of power associated with an unweighted rather
than weighted score,with the extent of the loss depending on the
variation in effect sizes (see e.g. Pierce et al., 2010; Burgess and
Thompson, 2013; Davies et al., 2014). Furthermore, the evidence
suggests that the bias properties of the weighted and unweighted
scores are robust to mis-speciﬁcations of the score, such as the
presence of gene–gene and gene–environment interactions, and
the mis-measurement of weights in a weighted score approach
(Burgess and Thompson, 2015). In our main analysis, we use an
unweighted allelic score, increasing the power of the instruments
and alleviating weak IV problems. However, we also explore the
alternative speciﬁcations discussed above in the sensitivity analy-
ses.
3.3. Examining the validity of the genetic variants in our
empirical applications
Using a total of 249,796 individuals from 64 different cohorts of
European ancestry, Speliotes et al. (2010) conducted a large-scale
GWAS meta-analysis. This conﬁrmed 14 known obesity susceptibil-
ity loci and identiﬁed 18 new loci, with no evidence of non-additive
effects, SNP × SNP interaction effects, or heterogeneity by sex or
study. We  use these 32 variants to explain variation in adiposity.
We next relate the speciﬁc choice of these variants to the assump-
tions for suitable use of genetic variants as instruments discussed
in Sections 2.2 and 2.3.
Assumption 1 (Independence). The independence assumption
may  be violated in the presence of population stratiﬁcation due
to ethnicity. For example, the allele frequencies of the SNP that
accounts for the largest proportion of the variance (FTO) are known
to vary by ethnic group (Frayling et al., 2007). Nevertheless, it is
not likely to be a problem here, as our cohort is recruited from a
speciﬁc geographically deﬁned region with a predominantly white
population. In addition, our analysis only includes children whose
5 We discuss these in more detail below, as well as in the Web  Appendix. In
short, however, these are NRXN3 (rs10150332), BDNF (rs10767664), GNPDA2
(rs10938397), LRRN6C (rs10968576), PRKD1 (rs11847697), GPRC5B (rs12444979),
CADM2 (rs13078807), SLC39A8 (rs13107325), TNNI3K (rs1514175), PTBP2
(rs1555543), FTO (rs1558902), NUDT3 (rs206936), FLJ35779 (rs2112347), MAP2K5
(rs2241423), QPCTL (rs2287019), NEGR1 (rs2815752), TMEM18 (rs2867125), LRP1B
(rs2890652), KCTD15 (rs29941), TMEM160 (rs3810291), MTCH2 (rs3817334),
MTIF3 (rs4771122), ZNF608 (rs4836133), RPL27A (rs4929949), SEC16B (rs543874),
MC4R (rs571312), RBJ (rs713586), FAIM2 (rs7138803), SH2B1 (rs7359397), FANCL
(rs887912), ETV5 (rs9816226), TFAP2B (rs987237), where the rs-number is an
identiﬁcation tag that uniquely positions the polymorphism in the genome.
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Table  1
Mean and standard deviation (SD) of adiposity for each SNP.
Original sample Genetic sample Estimation sample (KS3) Estimation sample (BP)
Outcomes Mean SD Mean SD Mean SD Mean SD
KS3 100 (10.0) 101*** (9.6) 103*** (8.9) 104*** (8.8)
Systolic BP 111 (11.5) 111 (11.3) 111 (11.2) 111 (11.2)
Diastolic BP 56.3 (8.39) 56.2 (8.28) 56.2 (8.28) 56.2 (8.28)
Treatments
Fat  mass 100 (10.0) 100 (9.8) 100 (9.8) 100 (9.7)
Instruments
Unweighted score 28.9 (3.47) 28.9 (3.5) 28.9 (3.45) 28.9 (3.44)
Weighted score 4.02 (0.53) 4.02 (0.53) 4.02 (0.53) 4.02 (0.53)
NRXN3 0.42 (0.57) 0.42 (0.57) 0.42 (0.58) 0.42 (0.57)
BDNF  1.59 (0.58) 1.59 (0.58) 1.59 (0.58) 1.60 (0.57)
GNPDA2 0.87 (0.70) 0.87 (0.70) 0.86 (0.69) 0.86 (0.69)
LRRN6C 0.63 (0.65) 0.63 (0.65) 0.63 (0.65) 0.63 (0.65)
PRKD1 0.09 (0.30) 0.09 (0.30) 0.09 (0.30) 0.10 (0.30)
GPRC5B 1.73 (0.49) 1.73 (0.49) 1.73 (0.49) 1.73 (0.49)
CADM2 0.40 (0.57) 0.40 (0.57) 0.40 (0.57) 0.40 (0.57)
SLC39A8 0.15 (0.37) 0.15 (0.37) 0.14 (0.36) 0.15 (0.37)
TNNI3K 0.85 (0.70) 0.85 (0.70) 0.85 (0.70) 0.85 (0.70)
PTBP2 1.18 (0.70) 1.18 (0.70) 1.18 (0.70) 1.19 (0.69)
FTO  0.81 (0.69) 0.81 (0.69) 0.81 (0.70) 0.82 (0.70)
NUDT3 0.39 (0.56) 0.39 (0.56) 0.39 (0.56) 0.39 (0.56)
FLJ35779 1.28 (0.67) 1.28 (0.67) 1.27 (0.67) 1.27 (0.67)
MAP2K5 1.57 (0.58) 1.57 (0.58) 1.57 (0.58) 1.57 (0.58)
QPCTL 1.62 (0.56) 1.62 (0.56) 1.62 (0.56) 1.62 (0.56)
NEGR1 1.20 (0.69) 1.20 (0.69) 1.19 (0.69) 1.18 (0.69)
TMEM18 1.66 (0.53) 1.66 (0.53) 1.66 (0.53) 1.66 (0.53)
LRP1B 0.34 (0.53) 0.34 (0.53) 0.34 (0.53) 0.33 (0.53)
KCTD15 1.37 (0.66) 1.37 (0.66) 1.37 (0.65) 1.38 (0.65)
TMEM160 1.39 (0.64) 1.39 (0.64) 1.38 (0.64) 1.39 (0.64)
MTCH2 0.80 (0.69) 0.80 (0.69) 0.80 (0.70) 0.80 (0.69)
MTIF3 0.46 (0.59) 0.46 (0.59) 0.46 (0.59) 0.47 (0.59)
ZNF608 0.99 (0.71) 0.99 (0.71) 0.99 (0.71) 0.99 (0.71)
RPL27A 1.08 (0.70) 1.08 (0.70) 1.09 (0.70) 1.10 (0.70)
SEC16B 0.42 (0.58) 0.42 (0.58) 0.42 (0.58) 0.42 (0.58)
MC4R 0.47 (0.60) 0.47 (0.60) 0.47 (0.60) 0.47 (0.60)
RBJ  0.98 (0.71) 0.98 (0.71) 0.98 (0.71) 0.98 (0.71)
FAIM2 0.72 (0.68) 0.72 (0.68) 0.72 (0.68) 0.72 (0.67)
SH2B1 0.83 (0.70) 0.83 (0.70) 0.82 (0.70) 0.82 (0.70)
FANCL 0.58 (0.65) 0.58 (0.65) 0.58 (0.64) 0.58 (0.65)
ETV5  1.65 (0.54) 1.65 (0.54) 1.65 (0.53) 1.66 (0.53)
TFAP2B 0.36 (0.54) 0.36 (0.54) 0.36 (0.54) 0.36 (0.54)
Covariates
Girl  0.48 (0.50) 0.49 (0.50) 0.51*** (0.50) 0.52*** (0.50)
Birth  weight 3404 (557.2) 3439*** (532.1) 3436*** (525.7) 3438*** (521.6)
Age  at KS3 (in months) 170 (3.73) 170 (3.77) 170 (3.68) 170 (3.71)
Ln  (income) 5.29 (0.49) 5.33*** (0.48) 5.35*** (0.46) 5.37*** (0.46)
Mother’s education
O-level 0.45 (0.50) 0.44 (0.50) 0.44 (0.50) 0.44* (0.50)
A-level 0.22 (0.42) 0.25*** (0.43) 0.26*** (0.44) 0.27*** (0.45)
University degree 0.12 (0.33) 0.15*** (0.35) 0.16*** (0.37) 0.17*** (0.38)
Not  natural father 0.92 (0.28) 0.93** (0.26) 0.93*** (0.25) 0.94*** (0.24)
Father’s social class ***
Managerial 0.34 (0.47) 0.36** (0.48) 0.36*** (0.48) 0.37 (0.48)
Non-manual skilled 0.12 (0.33) 0.12 (0.33) 0.13* (0.34) 0.13*** (0.34)
Manual skilled 0.31 (0.46) 0.29*** (0.45) 0.29 (0.45) 0.28*** (0.45)
Semi-skilled 0.10 (0.30) 0.09* (0.29) 0.08*** (0.27) 0.08*** (0.27)
Unskilled 0.03 (0.17) 0.02* (0.15) 0.02*** (0.14) 0.02*** (0.14)
Mum  works part-time 0.36 (0.48) 0.38* (0.48) 0.38*** (0.49) 0.39*** (0.49)
Mum  works full-time 0.10 (0.30) 0.11 (0.31) 0.11** (0.32) 0.11** (0.32)
Partner employed 0.88 (0.33) 0.89*** (0.31) 0.89 (0.32) 0.89 (0.32)
IMD  20.8 (14.9) 19.7*** (14.4) 18.7*** (13.7) 18.6*** (13.6)
Alcohol in pregnancy 0.55 (0.50) 0.56 (0.50) 0.57** (0.49) 0.58*** (0.49)
Smoke in pregnancy 0.24 (0.43) 0.21*** (0.41) 0.17*** (0.38) 0.16*** (0.37)
Breastfeed <1 month 0.16 (0.37) 0.16 (0.36) 0.16 (0.37) 0.15 (0.36)
Breastfeed 1–3 months 0.16 (0.36) 0.16 (0.36) 0.16 (0.37) 0.16 (0.37)
Breastfeed 4 + months 0.42 (0.49) 0.47*** (0.50) 0.50*** (0.50) 0.51*** (0.50)
Mother’s age: 20–24 0.18 (0.39) 0.16*** (0.37) 0.13*** (0.34) 0.13*** (0.33)
Mother’s age: 25–29 0.40 (0.49) 0.39 (0.49) 0.40 (0.49) 0.40 (0.49)
Mother’s age:30–34 0.28 (0.45) 0.31*** (0.46) 0.33*** (0.47) 0.34*** (0.47)
Mother’s age: 35+ 0.10 (0.30) 0.11** (0.31) 0.12*** (0.33) 0.12*** (0.33)
EPDS  score 6.88 (4.83) 6.68*** (4.69) 6.45*** (4.56) 6.34*** (4.51)
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Table 1 (Continued )
Original sample Genetic sample Estimation sample (KS3) Estimation sample (BP)
Outcomes Mean SD Mean SD Mean SD Mean SD
CCEI score 13.2 (7.78) 12.8*** (7.51) 12.6*** (7.31) 12.4*** (7.22)
Sample size 11,978 7335 4844 4047
Notes: Family income is an average of two observations (when the child is aged 3 and 4) and is in 1995 prices. It is adjusted for family size and composition (equalized)
using the OECD equivalence scale to allow for a comparison of incomes for all households. The social class variables use the standard UK classiﬁcation of social class based on
occupation (professional, managerial/technical, non-manual skilled, manual skilled, semi-skilled and unskilled). IMD  refers to the Index of Multiple Deprivation, and provides
a  relative measure of deprivation at small area level. EPDS and CCEI refer to the mother’s Edinburgh Postnatal Depression Score and the Crown-Crisp Experimental Index.
EPDS  indicates to what extent the mother is at risk of perinatal depression; CCEI captures a broader deﬁnition of mental health, measuring general anxiety, depression and
somaticism. Higher scores mean the mother is more affected. The descriptive statistics for the full sample, Column (1), are based on a maximum of 11,978 observations if
the  variable reported in the column has no missing values on any observations.
* p < 0.10,
** p < 0.05,
*** p < 0.01 refers to a test whether the mean is signiﬁcantly different from the mean in the original sample shown in Column 1.
mother describes herself and the child’s father as white, and we
adjust all analyses for 10 ancestry-informative principal compo-
nents. Furthermore, we investigate whether there is any evidence
of systematic variation in the covariates by genotype. Appendix B
presents the results, exploring whether the distribution of covari-
ates is the same across the instrument distribution. Although there
are no true pre-randomization variables, and signiﬁcant differ-
ences do not necessarily indicate violation of independence (see
also Section 2.3), we ﬁnd no evidence of systematic differences for
the different covariates, providing at least suggestive evidence of
randomization of the genetic variants.
Assumption 2 (Exclusion).  The exclusion restriction may  be vio-
lated in different situations. First, we note that those who carry the
adiposity-increasing alleles of any of the variants used here do not
necessarily become obese. The variants increase body weight by
a modest amount, with the majority of effect sizes below 500 g.
In addition, as individuals do not know their genotype, parents
are unlikely to notice the subtle difference in (children’s) size that
is related to their genotype. Hence, it is unlikely to observe any
strong responses to increased body weight, such as changing (chil-
dren’s) diets. However, the question remains whether there are
any more subtle responses to higher body weights. As it requires
large sample sizes and data on different parental preferences and
behaviours to explore that in detail, one cannot say with complete
certainty that behaviours are unaffected. Nevertheless, we  explore
this indirectly in our data, testing whether mothers’ behaviours or
characteristics6 are related to their genotype. In the Web  Appendix,
Table S1, we explore whether the distribution of covariates is the
same in groups deﬁned by the mothers’ genotype, showing little
evidence of systematic differences. This may  be because there sim-
ply are no differences in maternal behaviours by genotype, because
we lack sufﬁcient power to detect any differences, or because we
do not observe the behaviours that are affected by the genotype.
Second, we searched for and examine existing literature related
to the mechanism through which the variants may  affect fat mass.
Unfortunately, little is known about the physiological function
of most of our variants, with much of this work ongoing in the
medical literature. Nevertheless, there is evidence that some vari-
ants (FTO, MC4R)  are associated with an increased consumption
of fat and energy (see e.g. Timpson et al., 2008; Cecil et al., 2008;
Richmond and Timpson, 2012). The literature suggests that the
SNPs increase food intake due to diminished satiety (Wardle et al.,
6 Including her education, age, lone parenthood, employment, smoking, drinking,
duration of breastfeeding, locus of control, a ‘teaching score’, and two  scores indi-
cating her engagement with and interest in outdoor, and in indoor activities with
the child.
2008), rather than through pathways that affect our outcomes of
interest. Table S2 in the Web  Appendix brieﬂy lists what the 32 vari-
ants used here have been shown to be associated with. Although
the vast majority of associations are with adiposity-related phen-
otypes, we note that the variants are likely to be associated with
additional phenotypes not shown in the Table, either because stud-
ies that have explored these associations were underpowered, or
because studies have not (yet) investigated those relationships.
Depending on these additional associations, they may  invalidate
their use as instruments if they affect the outcome of interest
directly. Nevertheless, our current knowledge suggests that, in
addition to being related to adiposity and adiposity-related phen-
otypes (such as Type II diabetes), some variants havebeen shown
to be associated with allergic asthma and rhinitis (rs10767664),
hyperactivity/impulsivity (rs1307880, rs2241423), schizophrenia
(rs10150332 and rs13107325), inattention (rs206936), white mat-
ter integrity (rs2815752), and Alzheimer disease risk (rs4836133,
rs713586)7. We  explore the robustness of our results to excluding
these variants from the instrument setin the sensitivity analyses
below.
Third, pleiotropy or LD would bias the IV estimates if the variant
affects the outcome directly or if the linkage is with another vari-
ant that directly affects our outcomes of interest. We  explore maps
of the human genome to investigate LD, and ﬁnd no evidence that
the variants used here directly affect (or are in LD with variants
that directly affect) our outcomes of interest or its determinants.
More speciﬁcally, data from the International HapMap Project show
that the SNPs that replicate in a large number of independent sam-
ples for educational attainment (Rietveld et al., 2013) and blood
pressure (Ehret et al., 2011) are not in LD with those for fat mass
(Speliotes et al., 2010).
Fourth, for canalization to violate the exclusion restriction, the
presence of the fat related variant at conception would have to
result in different brain or blood vessel development in order to
counter any predicted adverse effect of fat mass on the outcome.
We believe this is implausible. Furthermore, there is no evidence in
humans that canalization occurs in relation to complex traits such
as fat mass.
In summary, we  do not know individuals’ behavioural response
to their genotype, the speciﬁc physiological functions or biological
pathways through which the variants affect the phenotype, and
whether the variants have multiple phenotypic effects. With that,
it is impossible to guarantee that Assumption 2, exclusion, holds.
For instance, it is possible that some variants’ pleiotropic effects
7 The associations with hyperactivity, impulsivity, and inattention were not repli-
cable in independent samples. For more information, see the Web  Appendix.
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Table  2
Mean and standard deviation (SD) of adiposity for each SNP.
Gene rs number Adiposity-increasing/other
allele
Homozygous for Adiposity
non-increasing allele
Heterozygous Homozygous for
adiposity-increasing allele
Mean SD Mean SD Mean SD
NRXN3 rs10150332 C/T 99.7 9.69 100.0 9.81 101.1 10.49
BDNF  rs10767664 A/T 99.6 10.43 99.4 9.31 100.1 9.94
GNPDA2 rs10938397 G/A 99.5 10.02 99.9 9.70 100.3 9.53
LRRN6C rs10968576 G/A 99.9 9.89 99.8 9.67 99.8 9.66
PRKD1 rs11847697 T/C 99.7 9.68 100.9 10.66 99.4 6.81
GPRC5B rs12444979 C/T 98.6 8.71 99.9 9.65 99.9 9.84
CADM2 rs13078807 G/A 99.6 9.61 100.3 10.01 99.6 10.27
SLC39A8 rs13107325 T/C 99.8 9.73 100.2 10.10 100.2 7.61
TNNI3 K rs1514175 A/G 99.7 9.75 99.7 9.51 100.5 10.44
PTBP2 rs1555543 C/A 99.5 9.67 100.0 9.89 99.7 9.65
FTO  rs1558902 A/T 98.9 9.28 100.1 10.00 101.0 9.95
NUDT3 rs206936 G/A 100.0 9.77 99.4 9.70 100.0 10.31
FLJ35779 rs2112347 T/G 99.3 9.82 99.9 9.75 99.9 9.78
MAP2K5 rs2241423 G/A 99.6 9.89 99.9 10.00 99.8 9.63
QPCTL rs2287019 C/T 99.3 8.72 100.0 9.89 99.8 9.77
NEGR1 rs2815752 A/G 99.2 9.11 100.1 9.92 99.7 9.86
TMEM18 rs2867125 C/T 98.0 9.12 99.3 9.43 100.1 9.92
LRP1B rs2890652 C/T 99.7 9.64 100.1 10.02 99.8 10.54
KCTD15 rs29941 G/A 98.9 9.73 99.8 9.67 100.1 9.86
TMEM160 rs3810291 A/G 99.3 10.48 99.6 9.60 100.2 9.79
MTCH2 rs3817334 T/C 99.7 9.64 99.5 9.63 101.0 10.38
MTIF3 rs4771122 G/A 99.8 9.81 100.0 9.82 99.3 8.98
ZNF608 rs4836133 A/C 100.2 10.01 99.7 9.64 99.8 9.78
RPL27A rs4929949 C/T 99.6 9.52 100.0 9.88 99.8 9.76
SEC16B rs543874 G/A 99.5 9.55 100.3 9.99 101.5 10.86
MC4R  rs571312 A/C 99.4 9.42 100.3 10.11 101.1 10.94
RBJ  rs713586 C/T 99.1 9.98 99.8 9.63 100.7 9.76
FAIM2 rs7138803 A/G 99.6 9.67 99.9 9.87 100.6 9.72
SH2B1 rs7359397 T/C 99.6 9.70 99.8 9.83 100.2 9.76
FANCL rs887912 T/C 100.0 9.66 99.7 9.93 99.8 9.71
ETV5  rs9816226 T/A 98.0 8.58 99.6 9.87 100.0 9.77
TFAP2B rs987237 G/A 99.7 9.74 99.9 9.81 101.1 9.98
have simply not yet been identiﬁed, or that there are other variants
that are in LD with our instruments that affect the outcomes of
interest, but have not yet been identiﬁed. Hence, similar to any
other IV approach, exclusion remains an assumption, as we  cannot
test for this directly.
Assumption 3 (Non-zero effect of the instrument on treatment).  The
prior ﬁndings of robust associations between the genetic variants
and fat mass, replicated in a large number of studies, justify their
use as instruments. Using standard statistical tests, we will examine
the strength of our instruments in the application below.
Assumption 4 (Monotonicity).  Finally, with random allocation of
genetic variants and the fact that individuals do not know their
genotypes, we assume that an individual who carries the risk allele
is at least as heavy as the same individual, had she not carried the
risk allele, satisfying monotonicity. Although we do not observe
individuals’ counterfactuals, the literature tells us that, at a group or
population level, those who possess the genetic variants are heavier
than those who do not.
As monotonicity can be violated by gene–environment inter-
actions, we examine this in two ways. First, we explore the issue
of such interactions indirectly, testing whether the association
between fat mass and our instrument differs in different ‘environ-
ments’. Although one can never observe all potentially relevant
gene–environment interactions, we explore the importance of a
set of environments that have been shown to be important for
child development, deﬁned by gender, the child’s birth weight,
breastfeeding duration, social class, mother’s education, income
and deprivation. The results (presented in Table S3 in the Web
Appendix) show little evidence of gene–environment interactions.
Second, we study the existing literature on gene–environment
interactions for fat mass. Kilpelainen et al. (2011) ﬁnd some
evidence of such interactions between FTO and physical activ-
ity, though only for adults: for the physically active, the FTO risk
allele increases the odds of obesity less than for the physically
inactive. They do not ﬁnd such interaction for children. Using a
sample of around 170,000 individuals, a recent study explores
whether genetic variants explain the variance of BMI  (as opposed to
the mean, as gene–environment interactions by construction lead
to variance inﬂation). They conclude that there are no common
genetic variants that account for a large proportion of variation
in environmental or phenotypic variability, ﬁnding no evidence of
widespread gene–environment interaction effects for BMI  (Yang
et al., 2012).
3.4. Descriptive statistics
Table 2 presents the mean adiposity for each of the 32 SNPs,
distinguishing between those who are homozygous for the adi-
posity non-increasing allele, heterozygous, and homozygous for
the adiposity-increasing allele. This shows that each of the indi-
vidual SNPs explain little of the variation in adiposity, leading to
low power in the IV analysis. Rather than using each of the individ-
ual SNPs, we therefore use an allelic score, deﬁned as the count of
the number of adiposity-increasing alleles. As we show below, this
explains a larger proportion of the variance in adiposity than the
individual SNPs, increasing the power of the instrument. In the sen-
sitivity analyses (Section 3.6), however, we also show the results
using different speciﬁcations of the instrument, including the 32
individual SNPs, the 64 alleles, and a weighted allelic score.
Fig. 1 shows a histogram of the number of adiposity-increasing
alleles carried by each child, showing a bell-shaped distribution.
On average, children carry 29 adiposity-increasing alleles (standard
deviation = 3.4), with the total number ranging between 14 and 42.
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Fig. 1. Distribution of the number of adiposity-increasing alleles carried by each
child.
3.5. Results
Table 3 presents the results. Panel A, columns 1 to 3 show the
association between fat mass and the KS3 score, systolic, and dia-
stolic blood pressure, conditional on the 10 principal components.
The relationship between fat mass and educational attainment is
negative, with a one standard deviation increase in fat mass associ-
ated with a 0.09 standard deviation decrease in test scores. Columns
2 and 3 show a positive association for blood pressure, with a one
standard deviation increase in fat mass associated with a 0.23 and
0.12 mmHg  increase in systolic and diastolic blood pressure respec-
tively; similar to approximately 0.02 of a standard deviation.
Panel B presents the ﬁrst-stage regression results, showing a
strong positive relationship between the instrument and child fat
mass. The strength of the relationship is shown by the ﬁrst stage
F-statistic. A value of 76 (KS3) and 69 (blood pressure) suggests the
instrument is strong. Translating the effect size into body weight, a
one standard deviation increase in the allelic score increases weight
by around 1.3 to 1.5 kg, though the exact amount will depend on
which alleles are carried by the individual, as there is much het-
erogeneity in the variants’ effect sizes on adiposity. For example,
each risk allele of FTO – the variant that has been shown to have
the largest effect size – increases body weight by approximately
1 kg for an average 11 year old, whereas the effect size for GNPDA2
increases body weight by just over 300 g.
The second stage IV results are presented in Panel C. Colum 1
shows no effects of fat mass on educational performance. Although
the IV estimate is of similar magnitude but opposite sign to that in
Panel A, the large standard errors preclude us from rejecting the
null of no effect. However, with a p-value of 0.054 for the Hausman
test, there is some support for the IV as opposed to the OLS estimate,
though any such judgement should be based on a synthesis of all
the evidence, rather than on this one test alone.
Column 2 and 3 show a positive effect of fat mass on both systolic
and diastolic blood pressure, with an estimate that is somewhat
larger than the OLS estimates in Panel A. The estimates suggest
that a one standard deviation increase in fat mass increases systolic
and diastolic blood pressure by 0.37 and 0.21 mmHg  respectively,
though the Hausman test suggests that there is insufﬁcient evi-
dence to reject the hypothesis that the OLS estimate is unbiased.
3.6. Sensitivity analyses
We  next report a set of sensitivity analyses, evaluating the
robustness of the results. First, we use different speciﬁcations of
the instrument. We  start by specifying the 28 mutually exclu-
sive instruments, indicating the number of adiposity-increasing
alleles carried by each child. Panel A of Table 4 presents the results,
showing no effect of adiposity on KS3, but a positive effect on
both systolic and diastolic blood pressure. The over-identiﬁcation
(Hansen J) test does not reject the null. However, as discussed
above, it is difﬁcult to interpret this in a heterogeneous treatment
effects framework, as a rejection may  simply point to treatment
effect heterogeneity.
Panel B of Table 4 uses the 32 independent genetic variants
as 32 instrumental variables. Panel C speciﬁes the number of
adiposity-increasing alleles for each variant as separate instru-
ments (i.e. 64 instruments), and Panel D uses a weighted allelic
score. The latter is similar to the count of the number of risk
alleles, but incorporates the fact that the variants have different
effect sizes. Indeed, although the bias properties of the unweighted
score have been shown to be robust to mis-speciﬁcation (e.g. due
to mis-measurement of weights, gene–gene or gene–environment
interactions), it leads to a loss of power. We therefore use a
weighted allelic score, where the weights at each locus are deﬁned
by the effect size of the variant on adiposity, estimated in an inde-
pendent meta-analysis (Speliotes et al., 2010). Despite the different
instrument speciﬁcations and their strength in the ﬁrst stage as
shown by the F-statistic, the results are similar.
Table 3
OLS and IV estimates of the average response in standardized KS3, systolic and diastolic blood pressure.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: OLS
Fat mass coefﬁcient and p-value −0.092 <0.001 0.227 <0.001 0.116 <0.001
95%  conﬁdence interval [−0.118, −0.065] [0.188, 0.266] [0.088, 0.144]
Panel  B: First stage IV
Unweighted allelic score 0.349 <0.001 0.365 <0.001 0.365 <0.001
95%  conﬁdence interval [0.270, 0.428] [0.279, 0.451] [0.279, 0.451]
Panel  C: Second stage IV
Fat mass coefﬁcient and p-value 0.114 0.301 0.373 0.006 0.205 0.041
95%  conﬁdence interval [−0.102, 0.331] [0.105, 0.642] [0.009, 0.402]
First  stage F-statistic 75.47 68.78 68.78
IV:  p-value, Hausman test 0.054 0.276 0.365
Number of observations 4844 4047 4047
Notes: Column 1, 2 and 3 show the results, where the outcome variable is KS3, systolic and diastolic blood pressure, respectively. All analyses control for ancestry-informative
principal components. 95% conﬁdence intervals in square brackets; p-value is the p-value for standard t-ratio.
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Table  4
IV robustness analyses: different speciﬁcations of the instrument.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Mutually exclusive instruments
Coefﬁcient and p-value 0.039 0.695 0.299 0.015 0.205 0.026
95%  conﬁdence interval [−0.16, 0.23] [0.06, 0.54] [0.03, 0.39]
First  stage F-statistic 8.90 8.20 8.20
IV:  p-value, Hausman test 0.183 0.962 0.482
IV:  p-value, Hansen J-test 0.862 0.574 0.531
Panel  B: 32 independent SNPs
Coefﬁcient and p-value −0.035 0.643 0.354 <0.001 0.093 0.195
95%  conﬁdence interval [−0.18, 0.11] [0.16, 0.54] [−0.05, 0.23]
First  stage F-statistic 4.93 4.38 4.38
IV:  p-value, Hausman test 0.508 0.176 0.859
IV:  p-value, Hansen J-test 0.039 0.594 0.602
Panel  C: No. of adiposity-increasing alleles for
each of the 32 SNPs
Coefﬁcient and p-value −0.031 0.647 0.372 <0.001 0.168 0.011
95%  conﬁdence interval [−0.16, 0.10] [0.20, 0.55] [0.04, 0.30]
First  stage F-statistic 3.11 2.63 2.63
IV:  p-value, Hausman test 0.277 0.082 0.267
IV:  p-value, Hansen J-test 0.422 0.531 0.144
Panel  D: Weighted allelic score
Coefﬁcient and p-value 0.080 0.370 0.452 <0.001 0.174 0.038
95%  conﬁdence interval [−0.10, 0.26] [0.23, 0.68] [0.01, 0.34]
First  stage F-statistic 116.7 101.3 101.3
IV:  p-value, Hausman test 0.049 0.045 0.482
IV:  p-value, Hansen J-test – – –
Panel  E: Selected instruments in weighted
score
Coefﬁcient and p-value 0.116 0.239 0.542 <0.001 0.182 0.037
95%  conﬁdence interval [−0.08, 0.31] [0.30, 0.78] [0.01, 0.35]
First  stage F-statistic 96.59 91.68 91.68
IV:  p-value, Hausman test 0.029 0.444 0.444
IV:  p-value, Hansen J-test – – –
Panel  F: Using only FTO and MC4R
Coefﬁcient and p-value 0.139 0.312 0.666 <0.001 0.230 0.082
95%  conﬁdence interval [−0.13, 0.41] [0.30, 1.03] [−0.03, 0.49]
First  stage F-statistic 24.54 21.81 21.81
IV:  p-value, Hausman test 0.078 0.011 0.340
IV:  p-value, Hansen J-test 0.403 0.192 0.147
Number of observations 4844 4047 4047
Notes: See notes to Table 3. Panel A shows the IV estimate using the mutually exclusive instrumental variables, indicating the number of adiposity-increasing alleles carried
by  each child. Panel B uses the 32 independent SNPs as 32 instruments. Panel C speciﬁes the number of adiposity-increasing alleles for each SNP as separate instruments
(i.e.  64 instruments). Panel D uses a weighted allelic score, where the weights at each locus are deﬁned by the effect size of the variant on adiposity, as estimated in an
independent meta-analysis (Speliotes et al., 2010). All analyses control for ancestry-informative principal components. 95% conﬁdence intervals in square brackets; p-value
is  p-value for standard t-ratio.
As discussed in section 3.3, some of the variants in our analyses
have been shown to associate with other, non-adiposity related,
phenotypes, such as asthma and schizophrenia. In Panel E, we re-
estimate the IV model with the weighted IV score that drops these
variants (see Web  Appendix) from the instrument set. In addition,
Panel F shows the estimates using only FTO and MC4R,  the two
variants that account for the largest proportion of the variation in
fat mass, as the instrumental variables. The estimates are similar,
suggesting that the ﬁndings are not sensitive to the deﬁnition and
speciﬁcation of the instruments8.
Second, we explore the potential problem of weak instruments
in more detail, using the critical values in Stock and Yogo (2005).
Although the weighted and unweighted allelic scores show strong
ﬁrst stage results, the F-statistic of approximately 8, 4 and 3 in
Panels A, B and C of Table 4 respectively, imply that the rel-
ative bias of the IV estimates is between 10% and 20% (Panel
8 The results in Panel E and F that use a restricted instrument set are also robust to
using an unweighted score, or using the variants/alleles separately as instruments.
A) and over 30% (Panels B and C), and the size distortion over
25%. We  therefore compare these estimates to different estima-
tors that suffer less from weak instrument bias, using LIML and
Fuller-k (with k = 1). The critical values in Stock and Yogo (2005)
show that, for example, with 27 instruments and a ﬁrst stage F-
statistic of 8.3, the size distortion in LIML is less than 10%, and
Fuller has a relative bias that is less than 5%. We  present the
LIML and Fuller (1) results for our speciﬁcation with the largest
number of instruments (i.e. 64 instruments, as in Panel C of
Table 4) in Table 5, showing similar estimates for the different
estimators, suggesting that our results are not driven by weak
instruments.
Third, we explore different deﬁnitions of the variable of inter-
est: fat mass. As we  discuss in the introduction, obese children
may  have different educational outcomes due to sleep disorders,
school absenteeism, or differential treatment by teachers, parents
and peers. This would suggest that there may  be non-linearities.
Hence, it is of interest to study whether there are substantially
different effects on education and blood pressure for underweight
and overweight children. We  examine the child’s underweight and
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Table 5
IV robustness analyses: LIML and Fuller(1).
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: LIML
Fat mass coefﬁcient and p-value −0.001 0.991 0.477 0.002 0.216 0.084
95%  conﬁdence interval [−0.196, 0.194] [0.179, 0.775] [−0.029, 0.462]
First  stage F-statistic 3.11 2.63 2.63
p-value, Hausman test 0.277 0.082 0.267
p-value, Hansen J-test 0.434 0.608 0.156
Panel B: Fuller(1)
Coefﬁcient and p-value −0.002 0.985 0.474 0.002 0.215 0.082
95%  conﬁdence interval [−0.195, 0.192] [0.180, 0.769] [−0.027, 0.458]
First  stage F-statistic 3.11 2.63 2.63
p-value, Hausman test 0.277 0.082 0.267
p-value, Hansen J-test 0.433 0.605 0.156
Number of observations 4844 4047 4047
Notes: The models include 64 instruments, indicating whether the child carries each of the adiposity-increasing alleles for each SNP (as in Panel C of Table 4). All analyses
control for ancestry-informative principal components. See also notes to Table 3.
Table 6
IV robustness analyses: different speciﬁcations of the variable of interest.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Pr(Underweight)
Coefﬁcient and p-value −5.861 0.315 −19.26 0.021 −10.56 0.065
95%  conﬁdence interval [−17.3, 5.6] [−35.66, −2.85] [−21.77, 0.64]
First  stage F-statistic 19.91 18.22 18.22
p-value, Hausman test 0.205 0.012 0.060
Panel  B: Pr(Overweight)
Coefﬁcient and p-value 3.916 0.310 13.31 0.009 7.117 0.044
95%  conﬁdence interval [−3.64, 11.47] [3.46, 22.49] [0.21, 14.03]
First stage F-statistic 45.49 40.24 40.24
p-value, Hausman test 0.106 0.139 0.242
Number of observations 4844 4047 4047
Notes: See notes to Table 3. Panel A presents the estimates for the effect of being underweight; Panel B shows the estimates for being overweight.
overweight status in the IV analysis, deﬁned as being in the bottom
and top 15th percentile of the fat mass distribution respectively.
We show the results using the (unweighted) allelic score as our
instrumental variable, though they are robust to using the different
instrument speciﬁcations. The results are presented in Table 6, with
panel A showing the estimates of being underweight, and panel B
presenting the effects for being overweight. These show that the
instruments are somewhat less predictive of both binary indica-
tors. However, with a ﬁrst stage F-statistic ranging between 18 and
45, it is sufﬁciently strong, and the results show a similar pattern to
those above. For Key Stage 3 (column 1), their imprecision means
we cannot reject the null of no effect. For blood pressure (columns 2
and 3), the estimates conﬁrm that being underweight substantially
decreases both systolic and diastolic blood pressure, whilst being
overweight leads to an increase.
Next, we explore the existence of heterogeneous effects of fat
mass on KS3 and blood pressure by gender. It may  be, for example,
that girls are more affected by potential peers’ differential treat-
ment related to their adiposity than boys. Table 7, Panels A and B,
present the results, showing a larger (positive) effect of adiposity
on educational attainment for girls than boys, though both remain
insigniﬁcantly different from zero. We also ﬁnd an increase in sys-
tolic blood pressure for both boys and girls, though no signiﬁcant
effect on diastolic blood pressure for boys. Although we  are not the
ﬁrst to ﬁnd such gender differences (see e.g. Doll et al., 2002), the
reasons for the differential effects by gender are unknown, with
some suggesting it may  be due to gender differences in the body
fat distribution (Janssen et al., 2004).
Finally, we  examine the robustness of the estimates to the
inclusion of different sets of covariates. As we  argue in Section
2.4, our main analysis does not control for any covariates other
than the 10 principal components, as any covariates are mea-
sured post-randomization and, with that, may  be affected by the
treatment or outcome. However, one could argue that some covari-
ates are determined prior to, or at the time of, conception, such
as child gender and some parental characteristics. Controlling for
these covariates may  therefore increase the precision of the esti-
mates. Table 8 presents the results controlling for the child’s gender
(Panel A), for gender, maternal educational attainment, paternal
social class, and the Index of Multiple Deprivation, measured at
birth (Panel B), and for the full set of background characteristics
mentioned in Appendix B (Panel C). We  specify the (unweighted)
allelic score as the instrumental variable. All ﬁndings are simi-
lar to the initial estimates: the large standard errors mean we
cannot reject the null of no effect on the Key Stage 3 outcome,
but we  ﬁnd strong positive effects on blood pressure. The con-
ﬁdence interval becomes slightly narrower when we control for
the full set of characteristics, but it does not affect the inter-
pretation of the ﬁndings. Taken together, these analyses show
no evidence that children’s fat mass affects their academic per-
formance, but that increased fat mass leads to a rise in blood
pressure.
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Table  7
IV robustness analyses: subgroup analysis.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Girls
Coefﬁcient and p-value 0.243 0.106 0.426 0.035 0.447 0.004
95%  conﬁdence interval [−0.05, 0.54] [0.03, 0.82] [0.14, 0.75]
First  stage F-statistic 43.43 33.65 33.65
p-value, Hausman test 0.008 0.263 0.020
Number of observations 2469 2089 2089
Panel B: Boys
Coefﬁcient and p-value −0.029 0.866 0.329 0.088 −0.043 0.767
95%  conﬁdence interval [−0.37, 0.31] [−0.05, 0.71] [−0.33, 0.24]
First  stage F-statistic 32.62 34.51 34.51
p-value, Hausman test 0.736 0.738 0.228
Number of observations 2375 1958 1958
Notes: See notes to Table 3. Panels A and B present the estimates for girls and boys respectively.
Table 8
IV robustness analyses: controlling for covariates.
(1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Covariates: gender
Fat mass coefﬁcient and p-value 0.111 0.319 0.379 0.006 0.206 0.042
95%  conﬁdence interval [−0.11, 0.33] [0.11, 0.65] [0.01, 0.40]
First  stage F-statistic 77.18 69.51 69.51
p-value, Hausman test 0.044 0.288 0.371
Panel  B: Covariates: gender, maternal
education, social class at birth, IMD
Fat mass coefﬁcient and p-value 0.092 0.342 0.379 0.007 0.206 0.046
95%  conﬁdence interval [−0.10, 0.28] [0.10, 0.66] [0.00, 0.41]
First  stage F-statistic 79.61 68.61 68.61
p-value, Hausman test 0.122 0.288 0.363
Panel  C: Covariates: all1
Fat mass coefﬁcient and p-value 0.090 0.322 0.374 0.008 0.201 0.052
95%  conﬁdence interval [−0.09, 0.27] [0.10, 0.65] [−0.00, 0.40]
First  stage F-statistic 81.56 69.35 69.35
p-value, Hausman test 0.156 0.284 0.382
N  4844 4047 4047
Notes: See notes to Table 3. All analyses control for ancestry-informative principal components.
1 All covariates includes: child birth weight, age at KS3 (in months), ln(income), mother’s educational attainment, a binary indicator whether the child was  raised by the
natural  father, social class at birth, dummy variables indicating whether the mother works part-time or full-time, and whether the partner is employed, the Index of Multiple
Deprivation (IMD, measured at birth), binary variables indicating whether the mother drank alcohol during pregnancy, and whether the mother smoked during pregnancy,
the  duration of breastfeeding, and mother’s age at birth. The deﬁnition of the covariates is given in the note to Table B1, Appendix B.
4. Conclusion and discussion
Economists have become increasingly interested in the effects
of behaviours such as smoking, drinking or excessive food intake on
economic outcomes. As these behaviours are endogenous and dif-
ﬁcult (if not impossible) to randomize in an RCT, estimating their
effects is difﬁcult. Many studies therefore attempt to ﬁnd instru-
mental variables, or exploit some natural experiment that shifts
the behaviour for some group, but not others, to identify their
causal impact. The increasing availability of biomedical data, in
combination with a growing medical literature on the effects of
carrying speciﬁc genetic variants, introduces a different approach
to the examination of certain risk factors on different outcomes.
This paper discusses the method of instrumental variables using
Mendelian randomization, and links this to the statistical potential
outcomes framework. Mendelian randomization provides a novel
approach to estimating the causal impact, and with that will be of
interest to economists to explore.
We  note that its suitability and applicability depends on a set
of (biological) conditions, as well as on the research question and
context. We  discuss the speciﬁc conditions that need to be met
for genetic variants to be used as instruments, and relate these to
the statistical assumptions necessary for identiﬁcation of the aver-
age causal response using instrumental variables. These conditions
have not been well deﬁned in the current social science litera-
ture, but understanding them is crucial to the appropriate use of
genotypes as instruments for modiﬁable risk factors.
We review these conditions in the context of two  empirical
applications. First, we  examine whether child fat mass causally
affects academic achievement, and second, we  study whether it
affects blood pressure. To study the effect of adiposity on our
outcomes of interest, a well-conducted RCT would randomize an
intervention that reduces fat mass and compare the outcomes
between the group that was  treated and the control group. Ran-
domizing adiposity, however, is difﬁcult. We show that, in such
cases, quasi-experimental designs such as Mendelian randomiza-
tion experiments can provide an interesting alternative approach.
We  use a set of 32 recently identiﬁed genetic variants as instru-
mental variables for fat mass to illustrate the key concepts. In these
illustrative examples, we  show the systematic approach required to
identify genetic variants as instruments. We  also use direct meas-
ures of fat mass, rather than the generally used BMI. OLS  shows
that leaner children perform better in school tests compared to
their fatter counterparts, and that fatter children have higher blood
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pressure. Our genetic IV analysis, however, shows no evidence that
children’s fat mass affects their academic performance, whilst we
ﬁnd that fat mass increases children’s blood pressure.
Our discussion of the conditions for the suitability of genetic
variants as instrumental variables and our application raise some
more general issues of the use of genetic variants as instruments.
First is the question whether genetic variants are powerful enough
to identify causal effects. In the illustrative case we examine, while
our instruments are not weak in a statistical sense their effects may
be too small to impact on the possible pathways to academic per-
formance. In other words, a 1–2 kg increase in fat mass may  not
lead to a large drop in self-esteem or an increase in absenteeism.
It is, therefore, perhaps not surprising that we ﬁnd no signiﬁcant
effect on academic performance. In contrast, our results on blood
pressure show strong evidence of an increase driven by elevated
fat mass. As intervention studies of weight reduction (see e.g. the
meta-analysis of randomized controlled trials by Neter et al., 2003)
have shown that a 5 kg weight loss is sufﬁcient to cause a reduc-
tion in systolic blood pressure of about 4 mmHg, this suggests that
even small changes in fat mass, such as those driven by genetic
variants,can identify changes in blood pressure with sufﬁcient pre-
cision (see also Timpson et al., 2009).
Hence, if small changes in the risk factor are sufﬁcient to shift the
outcome of interest, Mendelian randomization presents an inter-
esting approach. However, if the outcome of interest is only affected
by large changes in the risk factor, Mendelian randomization may
not be sufﬁciently powerful, as genetic variants generally shift the
risk factor by a relatively small amount. This is particularly relevant
for studies in economics, which are often interested in the effects of
different intermediate phenotypes (e.g. adiposity, smoking, drink-
ing) on economic outcomes. In contrast to various examples in the
medical literature, ﬁnding effects on such economic outcomes gen-
erally requires larger changes in the risk factor. With most genetic
variants having small effect sizes, this suggests they explain insuf-
ﬁcient variation in the risk factor to affect the outcome of interest.
With a rapidly growing medical literature on the effects of carry-
ing speciﬁc variants, one option is to wait for more variants to be
identiﬁed and to combine these into one a (weighted) count of the
number of risk alleles. This could increase the explained phenotypic
variation and with that, the precision of the estimates. But for the
type of physical attributes that economists have been interested in
such as fat mass or height, any additional variants are likely to have
even smaller effects than those already identiﬁed9.
A second issue is the credibility of the IV assumptions. Some of
these are testable, but others are not. In particular, the validity of
the exclusion restriction cannot be tested, and will never be known
with certainty, which makes Mendelian randomization a contro-
versial approach within the economics literature. Our paper has
discussed this in detail and highlighted the various ways through
which the use of genetic variants as instrumental variables may
lead to invalid inferences. With our limited understanding of the
functions of variants and the pathways through which they affect
outcomes, it is unlikely that we will understand their exact func-
tion and mechanism in the foreseeable future. Hence, we  argue
that genetic variants need to be used with care. Their appropriate
use requires that several conditions, which have not hitherto been
spelt out in the economics literature, are met. However, even if
these conditions are met, the sample sizes in data sets that contain
both genetic markers and outcomes of interest to economists may
be too small to obtain deﬁnitive results. Indeed, even with around
4000–5000 observations, our standard errors are relatively large.
9 For example, the most recent (at time of writing) GWAS identiﬁed an additional
56  BMI-associated loci, which generally have lower minor allele frequency and/or
smaller effect size estimates than previously known loci (Locke et al., 2015).
But with a rapid increase in the number of genome wide associa-
tion studies, and with a decrease in their costs, this may  change.
Finally, just as there are good and poor RCTs and studies using any
other identiﬁcation design and methodology, there are good and
poor Mendelian randomization studies. By highlighting the poten-
tial problems and showing the systematic approach required to
identify genetic variants as instruments, we  attempt to steer oth-
ers to carefully consider the different assumptions and conditions
needed for valid inference before jumping to their use.
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Appendix A. A brief introduction to genetics
Each cell in the human body contains a nucleus in which most
DNA (99.9995%) is kept. DNA is stored in structures called chromo-
somes, where each chromosome contains a single continuous piece
of DNA. All cells in the human body apart from germ cells contain
46 chromosomes, organized into 23 chromosome pairs: one copy of
chromosome 1–22 from each parent, plus an X-chromosome from
the mother and either an X or a Y chromosome from the father.
Locations (or loci) where DNA varies between people are
called polymorphisms. The most commonly studied form of poly-
morphism is a Single Nucleotide Polymorphism (SNP): a single
base-pair variation in a DNA locus. As chromosomes come in pairs,
humans have two base-pairs at each locus, called alleles. These
alleles can either be the same or different. The term genotype is
used to describe the speciﬁc set of alleles inherited at a particular
chromosome locus. For example, individuals can have one of three
genotypes of FTO: they can be homozygous for the common allele
(TT), heterozygous (AT), and homozygous for the rare allele of FTO
(AA). The visible or measurable effect of a particular genotype is
called the phenotype. The phenotype, or risk factor, we examine is
fat mass.
Many studies have examined the heritability of fat mass, deﬁned
as the proportion of the total variance that is explained by genetic
factors. These are most commonly calculated from twin studies,
comparing intra-pair correlations for a characteristic in monozy-
gotic twins with that in dizygotic twins. These studies generally
report large heritability estimates: between 0.4 and 0.7. A high heri-
tability however, does not imply that any individual genetic variant
has large phenotypic effects. For example, there are many SNPs
that affect human weight, though all with small effects: so-called
‘polygenes’. Together, these variants may  have a large phenotypic
effect.
Until recently, researchers mainly used a ‘candidate gene
approach’ to examine associations between individual genetic vari-
ants and a risk factor. This approach consists of testing a speciﬁc
hypothesis: based on biological knowledge, researchers exam-
ine the association between one particular variant (the candidate
genetic variant) and a risk factor. These studies produced many
false-positive ﬁndings (Colhoun et al., 2003) and were inefﬁcient.
Genome wide association studies (GWAS) followed, genotyping
500,000 to over 1,000,000 SNPs in one go and relating all SNPs to
the risk factorof interest in a hypothesis-free way. Stringent criteria
are used for GWAS p-values to take account of this hypothesis-free
approach. Studies are either two-stage studies, where one or more
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Table  B1
An indirect test of independence: regressing the covariate on the instruments.
Unweighted allelic score Weighted allelic score 32 independent variants
Coefﬁcient Standard error Coefﬁcient Standard error p-Value of F-test:
instrument-coefﬁcients jointly
equal to zero
Girl 0.00 (0.00) 0.00 (0.01) 0.560
Birth  weight (g) 2.62 (2.18) 19.22 (14.11) 0.550
Age  at KS3 (in months) 0.04*** (0.02) 0.16 (0.10) 0.341
Ln(income) 0.00 (0.00) 0.00 (0.01) 0.392
Mother’s education −0.00 (0.00) −0.00 (0.02) 0.341
Raised by natural father 0.00 (0.00) 0.00 (0.01) 0.731
Social class at birth −0.00 (0.01) −0.03 (0.03) 0.076
Mum  works part-time 0.00 (0.00) −0.01 (0.01) 0.971
Mum  works full-time −0.00 (0.00) −0.00 (0.01) 0.428
Partner employed 0.00 (0.00) 0.01 (0.01) 0.905
Index  of Multiple Deprivation −0.06 (0.06) 0.32 (0.37) 0.259
Alcohol during pregnancy 0.00 (0.00) 0.01 (0.01) 0.596
Smoke during pregnancy 0.00 (0.00) 0.00 (0.01) 0.697
Breastfeeding 0.00 (0.00) 0.00 (0.03) 0.080
Mother’s age at birth 0.00 (0.00) −0.00 (0.02) 0.076
*** p < 0.01; The p-value in the last column corresponds to an F-test of the coefﬁcients on the 32 instrumental variables jointly equalling zero; Ln(income) is measured when
the  child is aged 3–4 as is in 1995 prices; mother’s educational level is a categorical variable with four values (less than ordinary (O) level, O-level, advanced (A) level, and
university degree); social class is measured using the standard UK classiﬁcation of class based on occupation (professional (I), managerial and technical (II), non-manual skilled
(IIInm), manual skilled (IIIm), semi-skilled (IV) and unskilled (V)); the Index of Multiple Deprivation (IMD) is a measure of local area deprivation, measured at birth, referring
to  areas containing about 8000 persons; breastfeeding is a categorical variable (never, <1 month, 1–3 months and 3+ months); the sample contains 4846 observations.
GWAS is performed, after which the small number of SNPs that
reach GWAS levels of statistical signiﬁcance are typed in other inde-
pendent samples to examine the robustness. Alternatively, studies
consist of a number of independent GWAS containing a large total
sample size, where only those SNPs that have consistent associa-
tions across all studies are interpreted as robust.
Appendix B. Indirect test of independence of covariates and
genetic variants
Table B1 presents the coefﬁcients (standard errors) of a regres-
sion of the covariate in the ﬁrst column on the unweighted allelic
score (columns 1 and 2) or weighted allelic score (columns 3 and 4).
The ﬁnal column shows the p-value of an F-statistic testing whether
the coefﬁcients on the 32 independent variants jointly equal zero.
With random assignment of the genetic variants, there should be
no systematic variation in the covariates by genotype. Although
some coefﬁcients are signiﬁcantly different from zero, there is no
evidence of systematic differences for the different covariates, pro-
viding at least suggestive evidence of randomization of genetic
variants.
Appendix C. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhealeco.2015.10.
007.
References
Angrist, J.D., Graddy, K., Imbens, G., 2000. The interpretation of instrumental vari-
ables estimators in simultaneous equation models with an application to the
demand for ﬁsh. Rev. Econ. Stud. 67, 499–527.
Angrist, J.D., Imbens, G.W., 1995. Two-stage least squares estimation of average
causal effects in models with variable treatment intensity. J. Am. Stat. Assoc.
90  (430), 431–442.
Angrist, J.D., Imbens, G.W., Rubin, D.B., 1996. Identiﬁcation of causal effects using
instrumental variables. J. Am.  Stat. Assoc. 91 (434), 444–472.
Angrist, J.D., Pischke, J.-S., 2009. Mostly Harmless Econometrics: An Empiricist’s
Companion. Princeton University Press, Princeton.
Bartolucci, F., Grilli, L., 2011. Modeling partial compliance through copulas in the
principal stratiﬁcation framework. J. Am.  Stat. Assoc. 106, 469–479.
Bhatti, P., Sigurdson, A.J., Wang, S.S., et al., 2005. Genetic variation and willing-
ness to participate in epidemiologic research: data from three studies. Cancer
Epidemiol. Biomarkers Prev. 14, 2449–2453.
Bound, J., Jaeger, D., Baker, R., 1995. Problems with instrumental variables estimation
when the correlation between the instruments and the endogenous variables is
weak. JASA 90, 443–450.
Box, J., 2010. Commentary: on RA Fisher’s Bateson lecture on statistical methods in
genetics. Int. J. Epidemiol. 39, 335–339.
Boyd, A., et al., 2012. Cohort proﬁle: the ‘Children of the 90s’—the index offspring of
the  avon longitudinal study of parents and children. Int. J. Epidemiol., http://dx.
doi.org/10.1093/ije/dys064.
Bowden, J., Davey Smith, G., Burgess, S., 2015. Mendelian randomization with invalid
instruments: effect estimation and bias detection through egger regression. Int.
J.  Epidemiol., http://dx.doi.org/10.1093/ije/dyv080.
Burgess, S., Thompson, S., 2013. Use of allele scores as instrumental variables for
Mendelian randomization. Int. J. Epidemiol. 42, 1134–1144.
Burgess, S., Thompson, S., 2015. Mendelian Raondomization: Methods for Using
Genetic Variants in Causal Estimation. Taylor & Francis Group LLC, Boca Raton,
FL.
Campos, P., Saguy, A., Ernsberger, P., Oliver, E., Gaesser, G., 2006. The epidemiology
of  overweight and obesity: public health crisis or moral panic? Int. J. Epidemiol.
35, 55–60.
Cawley, J., 2004. The impact of obesity on wages. J. Human Res. 39 (2), 451–474.
Cawley, J., Han, E., Norton, E., 2011. The validity of genes related to neurotransmitters
as  instrumental variables. Health Econ. 20 (8), 884–888.
Cecil, J., Tavendale, R., Watt, P., et al., 2008. An obesity-associated FTO gene variant
and increased energy intake in children. N. Engl. J. Med. 359, 2558–2566.
Clarke, P., Palmer, T., Windmeijer, F., 2015. Estimating structural mean models with
multiple instrumental variables using the generalised method of moments. Stat.
Sci.  30 (1), 96–117.
Colhoun, H., McKeigue, P., Davey Smith, G., 2003. Problems of reporting genetic
associations with complex outcomes. Lancet 361, 865–872.
Davey Smith, G., Ebrahim, S., 2003. ‘Mendelian Randomization’: can genetic
epidemiology contribute to understanding environmental determinants of dis-
ease? Int. J. Epidemiol. 32, 1–22.
Davey Smith, G., Ebrahim, S., 2005. What can Mendelian randomisation tell
us  about modiﬁable behavioural and environmental exposures? BMJ  330,
1076–1079.
Davey Smith, G., Lawlor, D.A., Harbord, R., et al., 2008. Clustered environments and
randomized genes: a fundamental distinction between conventional and genetic
epidemiology. PLoS Med. 4, 1985–1992.
Davey Smith, G., 2007. Commentary. Capitalizing on Mendelian randomization to
assess the effects of treatments. J. R. Soc. Med. 100, 432–435.
Davey Smith, G., 2011. Use of genetic markers and gene–diet interactions for inter-
rogating population-level causal inﬂuences of diet on health. Genes Nutr. 6 (1),
27–43.
Davies, N., von Hinke, S., Farbmacher, H., Burgess, S., Windmeijer, F., Davey Smith,
G., 2014. The many weak instruments problem and Mendelian randomization.
Stat. Med., http://dx.doi.org/10.1002/sim.6358.
Didelez, V., Sheehan, N.A., 2007. Mendelian randomization as an instrumental vari-
able approach to causal inference. Stat. Methods Med. Res. 16, 309–330.
Didelez, V., et al., 2010. Assumptions of IV methods for observational epidemiology.
Stat. Sci. 25 (1), 22–40.
148 S. von Hinke et al. / Journal of Health Economics 45 (2016) 131–148
Ding, W.,  Lehrer, S.F., Rosenquist, N.J., Audrain-McGovern, J., 2009. The impact of
poor health on academic performance: new evidence using genetic markers. J.
Health Econ. 28, 578–597.
Doll, S., Paccaud, F., Bovet, P., Burnier, M.,  Wietlisbach, V., 2002. Body mass index
abdominal adiposity and blood pressure: consistency of their association across
developing and developed countries. Int. J. Obes. Relat. Metab. Disord. 26,
48–57.
Ehret, G., Munroe, P., Rice, K., et al., 2011. Genetic variants in novel pathways inﬂu-
ence blood pressure and cardiovascular disease risk. Nature 478, 103–109.
Sisher, R.A., 1952. Statistical methods in genetics. Heredity, 6, 1-12. Reprinted. Int.
J.  Epidemiol. 2010 (39), 329–335.
Flatt, T., 2005. The evolutionary genetic of canalization. Q. Rev. Biol. 80 (3), 287–316.
Fletcher, J.M., Lehrer, S.F., 2011. Genetic lotteries within families. J. Health Econ. 30,
647–659.
Frayling, T., Timpson, N.J., Weedon, M.N., et al., 2007. A common variant in the FTO
gene is associated with body mass index and predisposes to childhood and adult
obesity. Science 316, 889–894.
Frangakis, C.E., Rubin, D.B., 2002. Principal stratiﬁcation in causal inference. Biomet-
rics 58, 21–29.
Fraser, A., et al., 2012. Cohort proﬁle: the avon longitudinal study of parents and
children: ALSPAC mothers cohort. Int. J. Epidemiol., http://dx.doi.org/10.1093/
ije/dys066.
Guo, G., North, K., Choi, S., 2006. DRD4 gene variant associated with body mass: the
national longitudinal study of adolescent health. Hum. Mutat. 27, 236–241.
Hansen, L., 1982. Large sample properties of generalised method of moments esti-
mators. Econometrica 50, 1029–1054.
Hingorani, A., Humphries, S., 2005. Humphries. Nature’s randomised trials. Lancet
366, 1906–1908.
Hinney, A., Schneider, J., Ziegler, A., Lehmkuhl, G., Poustka, F., Schmidt, M.H., et al.,
1999. No evidence for involvement of polymorphisms of the dopamine D4 recep-
tor gene in anorexia nervosa underweight, and obesity. Am.  J. Med. Genet. 88,
594–597.
Imbens, G.W., Angrist, J.D., 1994. Identiﬁcation and estimation of local average treat-
ment effects. Econometrica 62 (2), 467–475.
Janssen, I., Katzmarzyk, P., Ross, R., 2004. Waist circumference and not body mass
index explains obesity-related health risk. Am.  J. Clin. Nutr. 79, 379–384.
Jin, H., Rubin, D., 2008. Principal stratiﬁcation for causal inference with extended
partial compliance. JASA 103, 101–111.
Kilpelainen, T., et al., 2011. Physical activity attenuates the inﬂuence of FTO variants
on obesity risk: a meta-analysis of 218,166 Adults and 19,268 Children. PLoS
Med. 8 (11), e101116.
Kivimäki, M.,  Davey Smith, G., Timpson, N.J., et al., 2008. Lifetime body mass index
and later atherosclerosis risk in young adults: examining causal links using
Mendelian randomization in the cardiovascular risk in young ﬁnns study. Eur.
Heart J. 29, 2552–2560.
Lawlor, D.A., Windmeijer, F., Davey Smith, G., 2008a. Is Mendelian randomization
“Lost in Translation”? Stat. Med. 27, 2750–2755.
Lawlor, D., Harbord, R.M., Sterne, J.A., et al., 2008b. Mendelian randomization: using
genes as instruments for making causal inferences in epidemiology. Stat. Med.
27, 1133–1163.
Locke, A., Kahali, B., Berndt, S., et al., 2015. Genetic studies of body mass index yield
new insights for obesity biology. Nature 518 (7538), 197–206.
Neter, J., Stam, B., Kok, F., et al., 2003. Inﬂuence of weight reduction on blood
pressure: a meta-analysis of randomized controlled trials. Hypertension 42,
878–884.
Norton, E., Han, E., 2008. Genetic information, obesity and labor market outcomes.
Health Econ. 17, 1089–1104.
Palmer, T.M., Lawlor, D.A., Harbord, R.M., et al., 2011. Using multiple genetic variants
as  instrumental variables for modiﬁable risk factors. Stat. Methods Med. Res.,
http://dx.doi.org/10.1177/0962280210394459.
Pierce, B.L., Ahsan, H., VanderWeele, T.J., 2010. Power and instrument strength
requirements for mendelian randomization studies using multiple genetic vari-
ants. Int. J. Epidemiol., dx.doi.org/10.1093/ije/dyq151.
Richmond, R., Timpson, N., 2012. Recent ﬁndings on the genetics of obesity: is there
a  public health relevance? Curr. Nutr. Rep. 1, 239–248.
Rietveld, C., Medland, S., Derringer, J., et al., 2013. GWAS of 126,559 individuals
identiﬁes genetic variants associated with educational attainment. Science 340,
1467–1471.
Rubin, D.B., 1980. Comment on ‘Randomization Analysis of Experimental Data: The
Fisher Randomization Test’ by D. Basu. J. Am.  Stat. Assoc. 75, 591–593.
Rubin, D.B., 2005. Causal inference using potential outcomes: design, modeling,
decisions. JASA 100, 322–331.
Sargan, J., 1958. The estimation of economic relationships using instrumental vari-
ables. Econometrica 26, 393–415.
Sheehan, N.A., et al., 2008. Mendelian randomization and causal inference in obser-
vational epidemiology. PLoS Med. 5, 1205–1210.
Sjölander, A., Humphreys, K., Vansteelandt, S., et al., 2009. Sensitivity analysis for
principal stratum direct effects, with an application to a study of physical activity
and coronary heart disease. Biometrics 65, 514–520.
Speliotes, E.K., et al., 2010. Association analyses of 249,796 individuals reveal 18 new
loci associated with body mass index. Nat. Genet. 42 (11), 937–950.
Staiger, D., Stock, J.H., 1997. Instrumental variables regression with weak instru-
ments. Econometrica 65 (3), 557–586.
Stock, J.H., Yogo, M., 2005. Testing for weak instruments in linear IV regression. In:
Andrews, D.W.K., Stock, J.H. (Eds.), Identiﬁcation and Inference for Econometric
Models Essays in Honor of Thomas Rothenberg. Cambridge University Press,
New York, NY, pp. 80–108.
Stock, J.H., Wright, J.H., Yogo, M.,  2002. A survey of weak instruments and weak
identiﬁcation in generalized methods of moments. J. Bus. Econ. Stat. 20 (4),
518–529.
Taylor, A., Davies, N., Ware, J., VanderWeele, T., Davey Smith, G., Munafo, M.,  2014.
Mendelian randomization in health research: using appropriate genetic variants
and  avoiding biased estimates. Econ. Hum. Biol. 13, 99–106.
Timpson, N.J., Emmett, P.M., Frayling, T.M., et al., 2008. The fat mass- and obesity-
associated locus and dietary intake in children. Am.  J. Clin. Nutr. 88, 971–978.
Timpson, N.J., Harbord, R., Davey Smith, G., et al., 2009. Does greater adiposity
increase blood pressure and hypertension risk? Mendelian randomization using
the FTO/MC4R genotype. Hypertension 54, 84–90.
von Hinke, S., Davey Smith, G., Lawlor, D.A., Propper, C., Windmeijer, F., 2011.
Mendelian randomization: the use of genes in instrumental variable analyses.
Health Econ. 8, 893–896.
von Hinke, S., Davey Smith, G., Lawlor, D.A., Propper, C., Windmeijer, F., 2012. The
effect of fat mass on educational attainment: examining the sensitivity of dif-
ferent identiﬁcation strategies. Econ. Hum. Biol. 10 (4), 405–418.
von Hinke, S., Davey Smith, G., Lawlor, D.A., Propper, C., Windmeijer, F., 2013. Child
height health and human capital: evidence using genetic markers. Eur. Econ.
Rev. 57, 1–22.
von Hinke, S., Wehby, G., Lewis, S., Zuccolo, L., 2014. Alcohol exposure in utero and
child academic achievement. Econ. J. 124, 634–667.
Wardle, J., Carnell, S., Haworth, C.M.A., et al., 2008. Obesity associated genetic varia-
tion in FTO is associated with diminished satiety. J. Clin. Endocrinol. Metab. 93,
3640–3643.
Yang, J., Loos, R., Powell, J.E., et al., 2012. FTO genotype is associated with phenotypic
variability of body mass index. Nature 490 (7419), 267–272.
